CN1607941A - Pharmaceutical compositions in particulate form - Google Patents

Pharmaceutical compositions in particulate form Download PDF

Info

Publication number
CN1607941A
CN1607941A CNA028260074A CN02826007A CN1607941A CN 1607941 A CN1607941 A CN 1607941A CN A028260074 A CNA028260074 A CN A028260074A CN 02826007 A CN02826007 A CN 02826007A CN 1607941 A CN1607941 A CN 1607941A
Authority
CN
China
Prior art keywords
dried particles
pharmaceutical composition
ingredients
diameter
dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028260074A
Other languages
Chinese (zh)
Inventor
C·R·黄
V·J·沙利文
J·黄
Z·王
J·A·米克斯塔
D·B·蒙特戈麦利
B·福德
A·B·威尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Becton Dickinson and Co
Original Assignee
Becton Dickinson and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson and Co filed Critical Becton Dickinson and Co
Publication of CN1607941A publication Critical patent/CN1607941A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A method of preparing a pharmaceutical composition is described, comprising 1) atomizing a liquid formulation of a therapeutic agent to produce an atomized formulation; 2) freezing said atomized formulation to form solid particles; and 3) drying said solid particles at about atmospheric pressure to produce a powder, wherein said drying is performed in the presence of vibration, internals, mechanical stirring, or a combination thereof. Another method is described, comprising 1) atomizing a liquid formulation of a therapeutic agent to produce an atomized formulation; 2) freezing said atomized formulation to form solid particles; and 3) drying said solid particles to produce a powder; wherein the atomized formulation comprises droplets having an average mean diameter of between about 35mu and about 300mu, and/or the powder comprises dried particles having an average mean diameter of between about 35mu and about 300mu. Compositions made by the above methods, and methods of using the compositions, are also described.

Description

Pharmaceutical compositions in particulate form
The present invention require to be registered on October 22nd, 2002 the interim patent 60/419959 of the U.S., be registered in the interim patent 60/339156 of 11 days the U.S. of calendar year 2001 December and be registered in the priority of the interim patent 60/331952 of the U.S. in November 19 calendar year 2001, it is reference that every patent is all drawn at this with its complete content.
Invention field
The present invention relates to such as the method for preparing dry state granular (for example powdery) pharmaceutical composition.This compositions is fit to be applied to such as (for example carrying out intranasal administration) such as mucosal tissues.Introduced compositions prepared according to the methods of the invention and described compositions has been applied to patient's method.The example of the present composition comprises insulin and influenza vaccines, and described influenza vaccines contain the code nucleic acid of inactivated virus particle or influenza hemagglutinin.
Background of invention
The method that forms the dry state pharmaceutical composition has been seen in report.For instance, these methods comprise steps such as precipitation, spray drying and/or mechanical lapping dry.Some is reported method employing anhydrous solvent, makes the dampness rapid evaporation, thereby shortens the processing time.But such solvent can destroy just at exsiccant pharmaceutical reagent (for example protein).Often reunite easily with the granule that the method in the report forms, and/or lack the required suitable dimension of best medical usage, density (for example bulk density), form and/or stability.
Therefore, need to overcome the dry state preparation of drug combination method of above-mentioned one or more defectives.
Summary of the invention
The present patent application relates to such as preparation powdered drug method for compositions, is included under the situation about existing such as vibration component, internals, mechanical agitation member or this several situation combinations, near under the non-pressurized pressure described compositions is being carried out drying.In another embodiment, the present invention relates to the method such as preparation granular (for example powdery) pharmaceutical composition, wherein powder comprises the dried particles of the about 35-100 μ of average diameter m.Compositions and these method for compositions of use have also been introduced with method for preparing.
Brief description
Can more completely be familiar with various characteristics of the present invention and attendant advantages in conjunction with the accompanying drawings.
Figure 1A is depicted as spraying of the present invention-frozen gas drying equipment sketch map.
Figure 1B is depicted as the spraying-freeze-dried device sketch map of band vibration component and internals.
16.SFD chamber 36. pumps
2. spray nozzle 20. cooling systems
48. heating tape 44. bypass valves
12. solution (liquid) 46. by-pass lines
28. filter 18. atomizing airs
38. valve 49. vibration sources
32. air filter 50. internals
Figure 2 shows that the reaction of serum antibody (Ab) to the IN input of various influenza vaccines ingredients.
Figure A0282600700071
Figure 3 shows that mouse serum Ab is to carrying out the reaction of immunity with pFLU-HA.
Figure 4 shows that the particle size distribution of the liquid virion of the Accuspray nozzle generation of measuring with laser diffractometry.
Figure 5 shows that the gene expression of the liquid pCMC-LUC of input IN luciferase afterwards.
Figure 6 shows that the gene expression of the luciferase of mouse behind the input IN pCMV-LUC.
Figure 7 shows that the serum Ab titre of carrying out after the pFLU-HA immunity.
Figure 8 shows that with the Accuspray nozzle ejection and by the scanning electron microscope (SEM) of the exsiccant SFD insulin of lyophilization and scheme.
Figure 9 shows that scanning electron microscope (SEM) figure of the SFD insulin among Fig. 8, but amplification is bigger.
Figure 10 shows that in SFD and the liquid insulin sample detection to amide (chemical degradation), detection be stability.
Figure A0282600700082
Figure 11 shows that the dampness and the drying time of the compositions that produces with the lyophilization gas method.
Gas flow rate, m/s ■ .219+.344 ◆ .469 ▲ .594  .719 * .844 o2.00
Figure 12 shows that the SEM image of the mannitol powder that produces with spray chilling gas drying method.
Figure 13 A is depicted as in the contrast that has and do not have the seroimmunity reaction of IN input SFD influenza vaccines under the situation of chitosan.
Figure 13 B is depicted as and is not having the 56th day the immunoreactive contrast of nasal mucosa behind the IN input SFD influenza vaccines under the situation of chitosan.
Figure 14 shows that moisture level (low dry gas flow velocity (.39m/s)) in not having the whole SFD method of vibration component and internals from vulcanizing the sample of collecting in bed top and bottom.
Figure 15 shows that from the granule SEM of fluid bed top formation sample in the time of 30 minutes.
Figure 16 shows that from the granule SEM of fluid bed top formation sample in the time of 60 minutes.
Figure 17 shows that permeability with two kinds of different exsiccant powder of gas velocity.Among the figure effect (V-FB-SFD) of flow velocity to the distillation time.
Figure 18 shows that the particle size distribution of mannitol particles freezing and that form by lyophilization by the Accuspray nozzle spray.Particle size distribution is passed through determination of laser diffraction.
Figure 19 shows that the sem photograph (SEM) of SFD purified insulin powder (than insulin/lactose moisture-proof gas more).
Figure 20 shows that SFD insulin/lactose composite powder is exposed to the SEM behind the normal temperature and pressure dampness.
Shown in Figure 21 is SD (spraying-drying) and SFD (spraying-freeze-dried) Sprinkle Caps after the capsule film rupture.Can't see the lactose that is retained in the SFD Sprinkle Caps.
Detailed Description Of The Invention
The present invention relates to such as granular (for example powdery) dry state preparation of drug combination method; Relate to compositions with these method preparations; Relate to method with these combination treatments patient.
One aspect of the present invention relates to the method for pharmaceutical compositions, and described method comprises following one or more step: nebulae inhalation disease or prophylactic liquid ingredients produce the atomizing ingredients; Freezing described atomizing ingredients forms solid granulates; Dry described solid granulates forms dried particles (for example powder).Described atomizing ingredients should comprise volume mean diameter (such as W.H.Finley in " suck pharmaceutical aerosol mechanics preliminary " definition, Academic Press, London, UK (2001)) between 35-300 μ m, more suitable droplet between about 50-300 μ m, and/or described powder comprises volume mean diameter between 35-300 μ m, more suitable dried particles between about 50-300 μ m.These droplets or particulate volume mean diameter are preferably between the 50-100 μ m.In a preferred embodiment, have an appointment at least 50% dried particles volume diameter average diameter about 80% within; Should have an appointment at least 50% dried particles volume diameter average diameter about 60% within.In a preferred implementation, described powder comprises average air power diameter (defining as W.H.Finley, the same) between about 8-140 μ m, should be between about 8-80 μ m, and more suitable dried particles between about 20-70 μ m.The method and compositions prepared by this method are called " spraying-freeze-dried " method or compositions at this.
The aforementioned pharmaceutical compositions granule has suitable dimensions, density and/or form, so that by the nose administration.Do not want to be bound by any particular theory, the present invention proposes following mechanism: after above-mentioned composition enters intranasal, just be sent to intranasal mucosa or nasal sinuses mucosa, they are here adhered rather than are pulled to the hole chamber, enter pulmonary system, adhere to like this said composition is adsorbed at faster speed than other treatment disease or prophylactic compositions ingredients.When the present composition is vaccine, set up the therefore minimizing of required time of effective antibody response, mucosal immunity power (being media with the IgA reaction for example) strengthens.Drop into this vaccine of the present invention at intranasal, can cause system and nasal mucosa IgA immunoreation simultaneously.
The present invention provides a kind of method of pharmaceutical compositions on the other hand, and it comprises following one or more step: nebulae inhalation disease or prophylactic liquid ingredients produce the atomizing ingredients; Freezing described atomizing ingredients forms solid granulates; Under situation about existing,, form dried particles (for example forming powder) near dry described solid granulates under the normal pressure such as vibration component, internals, mechanical agitation member or this several situation combinations.Here " near normal pressure " refers to the atmospheric pressure of about 0.5-5.Here " drying " refers to remove the volatile component of ingredients from the solid frozen particle.Described powder should comprise volume mean diameter between 35-300 μ m, and is more suitable between about 50-300 μ m, is preferably in the dried particles between the 50-100 μ m; And/or the volume averaging aerodynamic diameter of dried particles is between about 8-140 μ m, should be between about 8-80 μ m, more suitable dried particles between about 20-70 μ m.In a preferred embodiment, have an appointment at least 50% dried particles volume diameter average diameter about 80% within; Preferably have at least about the volume diameter of 50% dried particles average diameter about 60% within.In dry run, the frozen solid granule is preferably the fluidisation attitude.The method and compositions prepared by this method are called " spraying-freezing-normal pressure-drying " method or compositions.The benefit of production compositions in this way is that they can not reunited.
Other advantages of the present composition are, described compositions easily forms aerosol, has good stable, aseptic and emission dosage, can keep biological activity well, left drug is few in explosive-feeding processing device such as inhalation device, and reconfigures in liquid easily.Described granule has low bulk density, and this helps granule to form aerosol, for example is used for the respiratory tract drug delivery.Described granule is very fine, and they are transported easily.The inventive method can be controlled particle size distribution well.Therefore, the particle size distribution of the present composition is subjected to good control.Particulate form has reduced the probability of they reunions, can also further help to form aerosol.It is stable that described compositions keeps under non-freezing conditions, thereby compare with liquid formulation, and they are more convenient aspect accumulating, more economical.The present composition is particularly suitable for the large-scale inoculation vaccine.In an embodiment of the invention, invention compositions is by respiratory system administration (for example intranasal administration).The present composition is particularly suitable for intranasal administration, makes accurate aiming nasal mucosa target become possibility because be subjected to the particle size distribution of good control.Compare with injection (for example Intradermal or subcutaneous injection), the advantage by the respiratory system administration comprises adaptability and the immunoreation that improves the patient.Another benefit by respiratory tract administration is that it is non-invasion procedure, and is painless, is convenient to operation.
Those skilled in the art knows the character of bulk density.Solid material pulverize, after the levigate or processing, every particulate real density is all identical, but the geometric space that material occupies is big.In other words, be spheric as fruit granule, then geometric density is less than real density, and is similar little by 50%.
In the carrying or vibration processes of dusty material, smaller particles can get in the space between the larger particles, and the shared geometric space of powder reduces, thereby its density increases.At last,, then can not make the further compacting of natural particle, so just obtain the largest particles accumulation if do not exert pressure.
Under the condition that accumulation rate, accumulation force (whereabouts) and drum diameter are controlled, the condition of maximum deposition efficiency is highly repeatably.The measuring method of this bulk density British Pharmacopoeia method " apparent volume ", ISO 787/11 and ASTM about standard method of test B527, the D1464 of bulk density and D4781 in standard to some extent.
The present invention provides the method for above-mentioned pharmaceutical compositions on the other hand, wherein freezing step be by the ingredients that will atomize introduce that temperature is lower than that the cold fluid of liquid formulation freezing point or medium carry out (used here term " fluid " had both comprised gas, as Compressed Gas, also comprise liquid); The boiling point of wherein said fluid or medium or sublimation point are lower than the boiling point or the sublimation point of atomizing ingredients; Wherein drying is being undertaken by methods such as dry freeze near (making up under the situation about existing such as vibration component, internals, mechanical agitation member or this several situations) under the normal pressure, and wherein freezing and drying should carried out (making up under the situation of existence such as vibration component, internals, mechanical agitation member or this several situations) near in the non-pressurized cold air; Wherein treating disease or preventative reagent is protein (for example insulin), nucleic acid or virion, wherein therapeutic agent is an immunoreagent, as influenza vaccines (for example comprising the particulate vaccine of deactivation influenza), subgroup influenza vaccines or nucleic acid coding influenza hemagglutinin protein, wherein hemagglutinin should be subjected to the control of structural priming, particularly strong structural priming is as the CMV promoter; Wherein liquid formulation also comprises pharmaceutical excipient, as mucoadhesive, and for example chitosan, dermatan sulfate, chrondroitin or pectin, perhaps liquid formulation mainly is made up of therapeutic agent and water.
The present invention provides the pharmaceutical composition with method for preparing on the other hand; The pharmaceutical composition that perhaps comprises dried particles, the volume mean diameter of wherein said dried particles are between 35-300 μ m, and be more suitable between about 50-300 μ m, is preferably between the 50-100 μ m; And/or the average air power diameter of dried particles is between about 8-140 μ m, should be between about 8-80 μ m, more suitable between about 20-70 μ m.Should have an appointment at least in the compositions 50% dried particles volume diameter average diameter about 80% within; The volume diameter of more suitable 50% the dried particles of having an appointment at least average diameter about 60% within.
The present invention provides a kind of patient's of treatment method on the other hand, and it comprises the pharmaceutical composition according to the inventive method preparation of using effective dose to the patient, and/or the pharmaceutical composition with aforesaid properties; Wherein said compositions by in the respiratory system, intranasal, internal rectum, intravaginal, Sublingual or parenteral administration, should pass through intranasal administration, and/or described delivery of composition is arrived nasal mucosa.The present invention provides the method that reduces treatment disease or preventative reagent dosage on the other hand, and described consumption is that this method comprises the pharmaceutical composition of the present invention of using effective dose by intranasal to the patient to the required dosage of generation curative effect behind patient's Nasacort.The present invention provides a kind of immunoreactive method that causes on the other hand in patient's body, comprise the immune composition of the present invention of using effective dose to the patient, and wherein said compositions is by intranasal administration, and/or described compositions is influenza vaccines of the present invention.
The present invention provides the method for pharmaceutical compositions on the other hand, it is included under the situation about existing such as vibration component, internals, mechanical agitation member or this several situation combinations, near dry solids under the normal pressure, described solid particle is that the atomizing ingredients by cold therapy disease or prophylactic liquid reagent forms.
The present invention provides the method for pharmaceutical compositions on the other hand, it comprises the liquid formulation that described treatment disease of atomizing or preventative reagent form, produce the atomizing ingredients, follow freezing described atomizing ingredients, form solid particle, dry described solid particle, obtain powder, wherein dried powder comprises average diameter between 35-300 μ m, and is more suitable between about 50-300 μ m, is preferably in the dried particles between the 50-100 μ m; Wherein have an appointment at least 50% dried particles volume diameter average diameter about 80% within; The volume averaging aerodynamic diameter of described dried particles is between about 8-140 μ m.
Any treatment disease or preventative reagent all can be used for the inventive method and compositions.Here used " therapeutic agent " (claims " active agents " here sometimes or API) can produce the compositions of curative effect after referring to use in cell, tissue, organ or patient's body.After being applied to the patient, the compositions that comprises one or more therapeutic agent can produce " clinical effectiveness ".Here used term " clinical effectiveness " refers to useful clinically biological respinse, is applicable to diagnosis and treatment simultaneously.For example, the present composition can be used in the diagnostic test method, and/or be used for treatment, prevention disease of patient and/or alleviate disease symptoms.
Therapeutic agent can be an any kind, for example comprises polypeptide (protein), polynucleotide (nucleic acid), micromolecule such as steroid and virion.Term polypeptide and protein here are used interchangeably, and term polynucleotide and nucleic acid also are like this.
Suitable polypeptide or peptide include, but is not limited to somatomedin, cytokine, antigen, antibody, interleukin, lymphokine, interferon, enzyme etc., include, but is not limited to anti-IgE antibodies, organize plasminogen activity factor (tPA), calcitonin, erythropoietin (EPO), factors IX, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), growth hormone (particularly human growth hormone), heparin (comprising the low-molecular-weight heparin), insulin, quasi-insulin growthing factor I (IGF-I) and II (IGF-II), interleukin, interferon-ALPHA, β and γ, Alfasone, releasing hormone, Somat and analog, vassopressin and analog, follicle stimulating hormone, dextrin, cilary neurotrophic factor, somatotropin releasing factor, insulinotropic hormone, hugely have a liking for colony-stimulating factor (M-CSF), nerve growth factor, parathyroid hormone, α-1 antitrypsin, anti-rsv antibodies, deoxyribonuclease, Her2, CFTR (gallbladder cystic fibrosis transmembrane conduction regulator gene product, be used for the treatment of gallbladder cystic fibrosis), insulin etc.In a preferred implementation, polypeptide is an insulin.Also can adopt polypeptide such as labelled protein.
In a preferred implementation, polypeptide can be indicated in the infectious substance or on the surface, as antibacterial, virus, protozoacide or other parasites, comprises malaria etc.This peptide species can be at central immunoreagents that is used as such as vaccines.
Polypeptide can be natural, also can be that reorganization forms, and can carry out modification with art-recognized any method, as each peptide species of discussing among the US2002/0052475.Be used for the fragment that polypeptide of the present invention can be a full length protein, the appropriate polypeptide of virtually any size (length) can adopt.For example, comprising the polypeptide of one or more epitopes and/or antigen sequence can be as causing immunoreactive reagent.
Suitable polynucleotide comprise the carrier that contains recombination sequence etc., and described recombination sequence is a therapeutic target polypeptides coding.These polynucleotide can be above-mentioned or other any therapeutical peptide codings.Clone these sequences, target sequence and suitable expression control sequenc are effectively coupled together the generation recombinant vector, these methods all are very conventional methods.Typical method is seen and is set forth in Sambrook, J. wait work (1989) " molecular cloning---laboratory manual " (Molecular Cloning, a Laboratory Manual), Cold SpringHarbor Press, Cold Spring Harbor, NY and Ausubel, work such as F.M. (1995) " existing test report in the molecular biology " (Current Protocols in Molecular Biology), NY, John Wiley﹠amp; Sons etc.Term " expression control sequenc " refers to regulate the polynucleotide sequence of expression of polypeptides, and polypeptide is encoded by realizing the polynucleotide that function (" effectively ") connects with it.Expression can be controlled at the level of mRNA or polypeptide.Therefore, expression control sequenc comprises element relevant with mRNA and the element relevant with protein.These elements comprise promoter, (virus or cell) enhancer, ribosome binding sequence, transcription terminator etc.If expression control sequenc can realize or strengthen the expression of coded sequence in the present position, show that then expression control sequenc effectively has been connected on the nucleotide coding sequence.For example, when enhancer effectively was connected to 5 ' of coded sequence, enhancer just can promote the expression of coded sequence.Suitable expression control sequenc as strong constitutive property or scalable enhancer, is conspicuous for those skilled in the art.
Polynucleotide can be natural, the generation of also can recombinating.Be used for the fragment that polynucleotide of the present invention can be total length nucleic acid, for example give the fragment of full length protein fragment coding.The appropriate polynucleotide of virtually any size can adopt, as long as it can provide clinical efficacy.
The polynucleotide that are used for the present composition and method can have any form, and these forms are conspicuous for those of skill in the art, comprise DNA, RNA, PNA, LNA, oligonucleotide, sub-thread or bifilar molecule etc.Nucleic acid can comprise any amount of known altered contents, and these altered contents can promote the stable of nucleic acid or strengthen the absorption of cell to them.These altered contents comprise those that USP6455292 etc. is discussed.
In a preferred embodiment, polynucleotide are as vaccine, for example dna vaccination.Synthetic and the using method of this dna vaccination will be discussed (for example, can referring to embodiment 5-8) in detail in other places of this description, and this vaccine can be an influenza hemagglutinin protein matter coding, can alleviate some symptom of influenza infection at least.This nucleic acid can be full length protein or its fragment coding, for example can cause immunoreactive antigenic peptides.
Nucleic acid can comprise coding or non-coding (for example regulating) sequence.Except being the peptide coding, nucleic acid also can be antiallergic molecule or ribozyme.For the discussion of the antigen molecule or the ribozyme of some known type, can be referring to USP 6455292 etc.
Suitable virion comprises the virion of partially or completely deactivation, can be used as the antigen of vaccine, as influenza, RSV and poliovirus etc.In a preferred embodiment, virus can be inactivating influenza virus.Typical influenza strain comprises A/PR/8/34 and Port Chalmers strain etc.In being also included within the subgroup vaccine of conventional method preparation.In another embodiment, also comprise the conventional filterable virus carrier that is fit to interanasal administration, include, but is not limited to adenovirus vector or AAV carrier, comprise one or more genes to the therapeutic protein coding.Any suitable therapeutic genes can adopt, and comprises the gene of suitable treatment gallbladder cystic fibrosis etc.
Suitable steroid comprises the traditional steroid that is used for the treatment of asthma, bronchospasm or other diseases, and these are known for a person skilled in the art.
Goal treatment reagent begins available any conventional liq and makes liquid formulation.Described liquid is preferably liquid, aqueous, and for example water (for example injection high-quality water) or any conventional buffer, described buffer can saliferous, also can not contain.PH to buffer will select, so that the therapeutic agent of stable protein or selected other types, and those skilled in the art grasp easily.Usually, this pH is within the physiological pH scope, although some protein is stable equally in wideer pH scope, for example under condition of acidic pH.Therefore, the pH scope of original liquid ingredients should be between about 1-10, and is more suitable between about 3-8, especially should be between about 5-7.As is known to the person skilled in the art, there are a large amount of suitable buffer can supply to adopt.Suitable buffer includes, but is not limited to sodium acetate, sodium citrate, sodium succinate, ammonium bicarbonate and ammonium carbonate.Usually, the concentration of buffer is about 1mM-2M, should be about 2mM-1M, and the more suitable 10mM-0.5M that is about especially should be about 50-200mM.If there is salt in the solution, then the concentration of salt generally is about 1mM-2M, should be about 2mM-1M, and the more suitable 10mM-0.5M that is about especially should be about 50-200mM.Suitable salt includes, but is not limited to NaCl.
Liquid formulation can have any form, as solution, suspension, serosity or colloid.
Liquid formulation can be chosen wantonly and comprise one or more conventional pharmaceutical excipients." excipient " refers generally to the chemical compound or the material that add for the effect that improves the API ingredients.Such example has anti-low temperature agent and anti-solvent, can guarantee or improve the stability of protein in spraying-lyophilization or spraying-freezing-constant pressure and dry process after the adding, and powder-product is in the future long-time stability and flowability.The normally mobile relatively freely solid particle of suitable protective agent; with can thickening or polymerization after water contacts; be inhaled in the patient body or enter in the patient body by other modes after harmless substantially, and can obviously effect not take place with therapeutic agent, thereby change its biological activity.Suitable excipient includes, but is not limited to protein, as human albumin, bovine serum albumin, gel, immunoglobulin; Carbohydrate is as monosaccharide (galactose, D-manna are lain, sorbose etc.), disaccharide (lactose, trehalose, sucrose etc.), cyclodextrin and polysaccharide (Raffinose, maltodextrin, dextran etc.); Aminoacid, as monosodium glutamate, glycine, alanine, arginine, histidine, and hydrophobic amino acid (tryptophan, tyrosine, leucine, phenylalanine etc.); Methylamine is as betanin; Excipient salt is as magnesium sulfate; Polyhydric alcohol is as trihydroxy or more polyhydroxy sugar alcohol, for example glycerol, Chi Sue alcohol, arabitol, xylitol, sorbitol and mannitol; Glycerol; Polyethylene Glycol; Polypropylene glycol and oxirane addition polymers; Surfactant; Their combination.Preferred excipient comprises trehalose, sucrose and mannitol.Another kind of excipient mucoadhesive is commonly used to strengthen contacting of API and mucomembranous surface.The example of mucoadhesive comprises chitosan, dermatan sulfate, chrondroitin and pectin.In addition, in the liquid formulation that adapts to SFD process described here, can add conventional cosolvent, in order to improve the dissolubility of API.
If the use mucoadhesive, their consumption generally is about 1-95wt%, should be about 1-50wt%, and the more suitable 5-50wt% that is about especially should be about 5-20wt%.The concentration of anti-low temperature agent is generally between about 5-95wt%.
In one embodiment, dried powder of the present invention will combine with extender or carrier subsequently, reduces the concentration of therapeutic agent in the intravital powder of input patient; That is to say that the bolus volume of unit dose is suitable big.Also usable extenders improves the dispersibility of powder in dispersal device, and/or improve the transport property of powder.This is different with use extender or carrier in spraying-dry run.Suitable extender generally is crystalline solid (to avoid suction), includes, but is not limited to lactose and mannitol.Correspondingly, if add extender such as lactose, its additional proportion can change, and the therapeutic destination agent should be about 99 with the ratio of extender: 1-1: 99, more suitablely be about 1: 5-5: and 1, especially should be about 1: 10-1: 20.
Liquid formulation of the present invention can atomize with any conventional method.For example, liquid can pass through double flowing nozzle, high pressure nozzle or rotating disk spraying, perhaps utilizes the atomizing of soniclizer or vibratory orifice plate aerosol generator (VOAG).In one embodiment, liquid formulation is by high pressure nozzle, as BD AccuSpray nozzle atomization.
In a preferred embodiment, can optimize atomization condition, make the average quality diameter of atomised droplets be at least about 20 μ m, should be between about 35-300 μ m, more suitable between about 50-300 μ m, especially should be between about 50-100 μ m.Available conventional method is optimized droplet size.Contingent condition has atomization air flow, atomization air pressure, flow rate of liquid etc.Can also change the type and the size of nozzle.Be easy to measure the drop size with conventional method, as use laser diffractometry.The size of dried particles can be measured with routine techniques, as scanning electron microscope (SEM) or laser diffraction.For example, Fig. 4 and 18 is respectively the typical particle diameter distribution with the fluid sample of laser diffractometry mensuration and dry powder sample, and sample prepares with embodiment 1 described method.
In one embodiment, freezing atomizing particle is near dry under the normal pressure, and as discussed in other places of this description, the size of atomised droplets was at least about 20 μ m, should be between about 20-300 μ m, and more suitable between about 35-100 μ m or 50-100 μ m.
After the liquid formulation atomizing, drop is frozen into solid particle rapidly.After atomization steps, drop should be freezing immediately, and is perhaps almost freezing immediately.
In one embodiment, during freezing drop, drop is immersed in the cold liquid, its temperature is lower than the solidification temperature of the liquid formulation that forms atomized drop.In a preferred embodiment, the temperature of cold liquid is about-200 ℃ to-80 ℃, should be about-200 ℃ to-100 ℃, preferably is about-200 ℃ (liquid nitrogen temperature is about-196 ℃).Any suitable cold liquid can adopt, and comprises liquid nitrogen, liquid argon and hydrogen fluorine ether, or compressed liquid, as compressed liquid CO 2, helium, propane or ethane, or similar inert fluid, as known in the art.For example, in one embodiment, liquid therapeutic ingredients atomizes by spray nozzle, and this spray nozzle is positioned at the container top that holds suitable cold liquid such as liquid nitrogen.Drop with solidify immediately after cold liquid contacts.Embodiment 2 is exactly the inactivating influenza virus particulate composition with this freezing method preparation.
In another embodiment, drop solidifies in the process by the gas in the cooling chamber (for example cold air, nitrogen, helium or argon), and gas temperature is lower than the freezing point of drop.In a preferred embodiment, cold air temperature is about-5 ℃ to-60 ℃, and more suitable being about-20 ℃ is to-40 ℃.Available conventional method refrigerating gas, as utilize cooling coil, heat exchanger or cooler.Gas temperature can reduce with conventional method, for example produces the temperature that is lower than freezing point with liquid nitrogen, dry ice or similar low temperature agent.Embodiment 1a and 1b have introduced instrument and the method that is used to prepare the present composition, wherein atomized drop in by the process of suitable cooling chamber by gas cooled.
Behind the solid particle that formation is solidified, dried particles forms powder." drying " refers to that content liquid can ignore, and for example particulate water capacity makes it be easy to disperse to form aerosol, for example in suction apparatus.This water capacity is usually less than about 15wt% water, should be lower than 10%, more suitablely is lower than about 1-5%.
In one embodiment of the invention, solidify drop by dry freeze method (lyophilization under the vacuum) drying, employing be conventional dry freeze instrument.The method generally is called " spraying-freeze-dried " or SFD method, and the compositions for preparing with the method is called " spraying-freeze-dried " or SFD compositions.For example, in one embodiment, when granule spray into solidify in the container (for example Virtis freeze-dried bottle) that fills liquid nitrogen after, container can be connected in the conventional dry freeze instrument, then unnecessary liquid nitrogen vaporization is fallen.The aerosol that solidifies is dry within about 48 hours usually, and water capacity is less than about 1wt%.Perhaps, drop is being solidified near in the non-pressurized cold air, and choose wantonly, put into the dry freeze bottle then and carry out dry freeze in condition lower part drying near normal pressure (as described below).
In another embodiment, the drop that solidifies is passing through sublimation drying near in the non-pressurized dry cold airflow (for example air, nitrogen or helium).Here used " near normal pressure " refers to the atmospheric pressure of about 0.5-5.Gas temperature can reduce by any conventional method, for example uses liquid nitrogen, dry ice or similar low temperature reagent.Exsiccant like this granule of the present invention is called " spraying-freezing-normal pressure-drying " granule sometimes.In a preferred implementation, atomized drop is freezing and dry in same " spraying-freezing-normal pressure-drying " chamber, makes freezingly and dry to finish in the same step.
A set of equipment of drying solid frozen particle and the USP4608764 that method is seen Leuenberger in approaching non-pressurized cold air.Be also shown in embodiments of the invention 1a and 1b.The conventional equipment of other types also can use.
In a preferred implementation, as described in embodiment 1b and 11, freezing atomizing particle is near in the non-pressurized cold air, and is dry under the condition that can promote the granule atomizing.In most preferred embodiment, freezing atomizing particle is in dry run, and is dry under the situation that vibration component, internals, mechanical agitation member or this several situation combinations exist.Here used term " internals " refers to any physical barriers object in chamber (for example SFD chamber) or the fluid bed, and for example catch, baffle plate or other stop object.This processing can make granule reach fluidized state.The method and apparatus that reaches this fluidized state is discussed in embodiment 1b and 11.
Embodiment 1b and 11 described method and apparatus can also prevent channel.Channel is one of worst fluidization characteristics of fine granular, can occur under low fluidizing velocity or high fluidizing velocity.When gas made progress by the space between distributor and the bed surface, channel just took place.These vertical channels laterally move past fluid bed in time, and the fluidization of bed is stopped.Also have gap on the bed, infiltrate in these vertical channels.Along with the increase of air velocity, the granule for some extreme viscosity not only forms little channel, and forms big channel, also claims rat hole.Why producing this problem, is because intergranular active force is obviously more much bigger than the power that fluid is applied on the granule.
Be difficult to fluidisation with spraying-refrigerated powder such as double flowing nozzle, high pressure nozzle or ultrasonic nozzle.When dry, these granules are easy to form channel or reunite, and make their be difficult to finish-drying not even rapidly on fluid bed.The present inventor recognizes, in dry run, introduce vibration component, internals, mechanical agitation member or integrated use they, can make these granule generation fluidisations effectively.
In another embodiment, freezing droplet can distil and the dry freeze combined drying in exsiccant cold air (for example air) by above-mentioned near under the normal pressure.For example, can will transfer in the dry freeze device further dry near the exsiccant compositions in normal pressure lower part (for example forming cake or the powder that still comprises excess liq).
Available conventional method is collected dry compositions.In one embodiment, dried particles can be collected by filter, moves then and does medical application.Understand the equipment that this method and this method adopts, can be referring to embodiment 1a and 1b and Figure 1A and Figure 1B.In another embodiment, spraying-freezing-normal pressure-dried particles is collected in the product container.The part dried particles can form loose cake, and further distillation can be removed wherein residual moisture in dry cold air stream, also they can be transferred in dry freeze device or other the suitable devices, further decompression (being lower than normal pressure) drying.
Basic identical with the character (for example particle diameter, permeability etc.) that above-mentioned any method dried granules is had.
Gas atomization of the present invention-freeze-dried process has particularly utilized the process of vibration component and/or internals, and a kind of economically viable method that can produce dried particles and can increase productive rate is provided.Have by the compositions of described method preparation and to be convenient to by character such as respiratory system administrations.Spraying-freeze-dried method of being introduced with the United States Patent (USP) 6284282 of Maa is different, and embodiments of the present invention only just can produce dried particles with a set of equipment.Atomizing among the present invention, freezing and dry should finishing at same container do not need to shift sample, thus can contaminated samples, can not reduce productive rate yet.Whole operation also can be finished continuously, thereby has improved efficient." continued operation " refers to not exist intermittently between each step, and/or do not relate to physical separation (for example not needing the transfer of granules of freezing atomizing dry in another container).Other sprayings-freeze-dried technology of pharmaceutical compositions often comprises another dry freeze step, and it need be transferred to frozen particle in the dry freeze device from spraying-refrigerating chamber.This additional step has reduced the commercial viability of spraying-freeze-dried technology, and because the moisture that is wrapped in the granule is partially thawed, granule is reunited easily.
After drying was finished, the present composition can form free-pouring powder.Size (geometric diameter) and shape before the dry porous particle of described compositions and the freezing droplet drying are roughly the same.
Dried particles of the present invention has required aerodynamic property.The inertial collision of dried particles and gravity descent property have determined their deposit properties in the animal breath road.The conventional method of available this area is measured this deposit properties.For example, aerodynamic diameter is defined as the subduplicate product (d of actual particle diameter and the ratio of grain density and water density Ae=(sg) 1/2d p, sg=ρ Granule/ ρ Water, d wherein AeBe the granule aerodynamic diameter, d pBe particle diameter).
Dried powder of the present invention also has other required character.Embodiment 9 and 10 has introduced the ρ for example with the present invention GranuleSome character of the analgesic composition of method preparation.Described granule has required form (shown in SEM) and density.In addition, described granule residual powder wherein after using conveyer device is few, demonstrates than better stability such as liquid insulin ingredients, and forms again in liquid easily.
The present composition can be used to treat various diseases, comprising diabetes, infectious disease or available any disease that description is treated at the therapeutic agent or the other treatment reagent of other local discussion.In a preferred implementation, the present composition is a vaccine.
One aspect of the present invention provides a kind of method that the patient of needs treatments is implemented to treat, comprise to described patient use effective dose, with the pharmaceutical composition of the inventive method preparation." effective dose " refers to cause the amount of required reaction here.For example, the immune composition of effective dose is meant that this dosage can effectively cause and can surveys immunoreation.Effective dose can be determined according to conventional methods by rule of thumb, consider various common factors, and as patient age, body weight and/or clinical condition, medication and time dosage are arranged, or the like.The patient can be any animal, is preferably mammal, for example farm-animals or domestic animal, and perhaps mouse, hamster, Cavia porcellus, rabbit etc. more are preferably the people.
The present composition can be used with any approach known to the those skilled in the art, includes, but is not limited to respiratory system, intranasal, internal rectum, intravaginal, Sublingual, oral cavity or parenteral route.In one embodiment, described compositions is applied in the mucosal tissue, includes, but is not limited to the mucosal tissue of nasal passage and nasal sinuses.In a preferred implementation, the present composition is granted the patient by respiratory system." by the respiratory system administration " refers to that here medicament enters pulmonary in some cases subsequently by nasal cavity and nasal sinuses by nose (intranasal) administration.
Can adopt conventional medication.Suitable administration apparatus (for example inhaler) is known in this area.Typical explosive-feeding processing device includes, but is not limited to the device that USP 09/879517 (being registered in 6/12/01) and 09/758776 (being registered in 1/12/01) are introduced.Dosage can be determined according to conventional method well known by persons skilled in the art.For example, compile " pharmacological basis of treatment ", Macmillan Publishing Co., New York referring to Goodman and Gilman.The factor of considering comprises the activity of concrete institute with medicament, the metabolic stability of medicament and the order of severity of action time, mode of administration and time, drug regimen, discharge rate, the species of receiving treatment, patient's age, body weight, general health situation, sex, diet situation and specified disease.The dosage (for example effective vaccinated dosage) that causes effective immune response is familiar with to those skilled in the art.
It is a kind of to the method for patient's administering therapeutic compositions with treatment health disorders (for example uncomfortable or disease) that the present invention provides on the other hand, comprises patient's nasal passage and/or nasal sinuses passage mucosal administration pharmaceutical composition of the present invention.Another embodiment is to patient's administering therapeutic method for compositions, comprises patient's nasal passage and/or nasal sinuses passage mucosal administration pharmaceutical composition of the present invention.Another embodiment relates to the unit dose of administrator or Diskus, comprises the effective dose of pharmaceutical composition of the present invention.
With the dried agent of other liquid formulation or other types, to compare as spraying-dry ingredients, the present composition utilizes intranasal administration, can obtain better therapeutic.Referring to embodiment 2 and 3.Therefore, when the present invention relates to that the patient implemented intranasal administration, reduce the amount that produces the required therapeutic agent of curative effect, it comprises the pharmaceutical composition of the present invention by the intranasal administration effective dose to described patient.
On the one hand, the present invention relates to excite the immunoreactive method of patient, comprise the immune composition of the present invention of using effective dose to the patient.Here used term " immunoreation " comprises various mechanism, for example when antigenic substance is invaded in the cell of many cells tissue or the extracellular liquid, and just the create antagonism antibody of antigenic substance of cell tissue.The antibody of Chan Shenging can be any in all kinds of immune antibodys like this, as immunoglobulin A, D, E, G or M.Also comprise the reaction of other types, for example cell and humoral immunity.Antigenic immunoreation has been obtained further investigation, and wide coverage has been arranged.Immunologic summary is seen that Roitt I. shows (1994) " amynologic basis " (Essential Immunology), Blackwell ScientificPublications, London.Immunization method is that conventional method is (for example, referring to volumes " the existing test report of immunology " such as John E.Coligan, John Wiley﹠amp; Sons., Inc.).
On the one hand, the present invention relates to vaccine (being used for stimulating the immune reagent of biological tissue) for the injury that may occur in the future provides protection.For example, influenza vaccines can prevent the infection of influenza virus at least on limited extent.That is to say that vaccine can be alleviated some symptom that influenza infection causes at least.Vaccine combination of the present invention can have protein (as subgroup vaccine), virion or be the form of target antigen coded DNA.
Embodiment 2 has introduced preparation the present invention spraying-freeze-dried (SFD) method for compositions, and said composition comprises the inactivating influenza virus granule.This embodiment introduced specific influenza virus strain using method.Those skilled in the art are not difficult to recognize, other influenza strains also can use.
Most of infectious agents produce the Pathophysiology effect by mucosa after entering in the body.In the inlet primary importance, the mucosa IgA that produces by the part can provide protection at infectious disease to the inhibition of infectious agents.Though traditional immunization route (as IM, ID etc.) is easy to the initiating system immunoreation, mucosa reaction generally is difficult to realize.The advantage of intranasal (IN) delivery of dry powder vaccine is that it is initiating system and mucosal immunoreaction simultaneously.In addition, the conveying of IN powder vaccine can reduce required dosage, because the suction of mucosa powder medicine is effective.
Embodiment 2 shows that carrying more by the antibody and the muscle that the spraying that contains excipient-the freeze-dried influenza vaccines are produced of intranasal conveying, the antibody that vaccine produced of multiple dose equates.
Embodiment 3 shows that SFD deactivation influenza granule can cause IgG and IgA reaction, if do excipient with chitosan, then this reaction can be enhanced.
Embodiment 4 is to the influenza Study on Stability.The dry freeze method can not cause negative effect to particulate stability, but particulate grinding then makes granule stability sharply descend to freeze-dried.
Embodiment 5-7 has introduced preparation and the using method of DNA influenza vaccines.The inventive method can be used for preparing and/or carrying the vaccine combination that comprises dna molecular.Produce dna vaccination, for example the method for influenza vaccines is known in this area, discusses in other places as this description.Embodiment 5 has introduced a model system, in this model, will be marker gene coded DNA plasmid by the intranasal mode, the luciferase of Lampyridea is introduced in the mouse body, this plasmid can be a liquid formulation, also can be dried (FD) ingredients prepared according to the methods of the invention.Being expressed in the nose tissue of luciferase gene is observed, rather than in the lung tissue.IN poudrage gained gene expression dose can be compared with liquid formulation.Embodiment 6 and 7 has introduced how to prepare the dna vaccination that comprises influenza hemagglutinin (HA) coded sequence, and with the remarkable reaction of this vaccination to mouse back initiation on one's body.The SFD ingredients that contains the excipient trehalose prepared according to the methods of the invention is by behind the intranasal administration, and the antibody response of initiation compares by the liquid formulation of the similar dosage of intranasal administration or much better than by the ingredients of muscle administration.
Embodiment 8 has introduced a kind of immunization protocol, and wherein basic vaccination is undertaken by the dna encoding influenza hemagglutinin, produces a large amount of influenza virus particles subsequently.This scheme can produce extra high antibody response.
On the other hand, the present invention relates to be used for the pharmaceutical composition of respiratory system administration, it comprises insulin; Also relate to the method for preparing compositions and treat the patient with said composition.Carry insulin to have several advantages by respiratory system, for example compare with administering modes such as Intradermal or subcutaneous injections, it can increase patient's adaptability, and diabetics needn't be injected continually voluntarily.Embodiment 9 and 10 has provided some character of insulin ingredients of the present invention.
Among the embodiment 2-10 that here provides, compositions is called " SFD " sometimes by the preparation of spraying-freeze-dried (dry freeze) method.In the compositions of these embodiment, particulate average diameter is at least about 20 μ m.These compositionss can be compared (embodiment 1,11 and 12) with spraying-freezing-normal pressure-drying means, and therefore above-mentioned discovery is equally applicable to the compositions with a kind of method preparation in back.Pro-is addressed in the following examples, and all temperature are all degree centigrade to be unit, and are not calibrated; Except as otherwise noted, all part and percents all refer to weight portion and percetage by weight.
Embodiment
Embodiment 1
1a) the method and apparatus of preparation the present invention spraying-freezing-normal pressure-dry pharmaceutical compositions
Many equipment all can be used to make pharmaceutical composition of the present invention.Fig. 1 has shown the overall schematic 10 that can be used for spraying of the present invention-freezing-normal pressure-drying equipment.Be to be used to prepare active medical components (API) below, for example be fit to method example with the API of respiratory system administration.Liquid feeding line 12 realizes that with atomizer 14 fluid is connected.The mixture of API and a kind of suitable liquid of packing in the liquid feeding line will further be explained below.Nozzle 14 is arranged on spraying-freezing-normal pressure-hothouse 16 inside.In a preferred implementation, atomizing line 18 (for example adopting Compressed Gas) carries out the interface with nozzle 14 and contacts, so that aerosolized mixture.Atomization gas can comprise nitrogen, oxygen or air.The nozzle of other general types also can effectively produce suitable atomizing particle size, comprises double-current nebulizer, high-pressure atomizer, ultrasound atomizer, is more preferably vibration implication colloidal sol generator (VOAG), known they each can both produce more uniform particle size distribution.Cold liquid (for example nitrogen) or solid (for example dry ice) can be placed in the hothouse, help the atomized drop rapid solidification.
Cooling system 20 makes the temperature in the chamber 16 generally maintain pact-20--40 ℃ at elementary drying stage for hothouse 16 provides cold air.Temperature in the hothouse 16 should keep below the freezing point of mixture.Cold air is provided by secondary cooling chamber 22, this cooling chamber liquid nitrogen, solid CO 2Or similar coolant produces the temperature that is lower than freezing point.Even there are needs to close in the cooling chamber 22, secondary cooling chamber 22 also can be kept system's running neatly.Cold air input line 24 provides the normal pressure frozen air from cooling system 20 to hothouse 16.Cold air return wire 26 is accepted the cold air from hothouse 16, and makes cold air return cooling system 20, thereby keeps dry loop between chamber 16 and the cooling chamber 22.Filter 28 is placed in 16 inside, chamber, should be between nozzle 14 and cold air return wire 26.Filter 28 is collected spraying-freezing-normal pressure-dried particles of API, and API can restore from granule, in order in the future medical.
Between cooling system 20 and hothouse 16, the temperature maintenance that is used for making the cold air that enters hothouse 16 is within required scope in cold air input line 24 for temperature controller 30.Additional gas filter 32 between chamber 16 and cooling system 20, is used for collecting the residuals of escaping from from chamber 16 in cold air return wire 26, thereby avoids polluting cooling system 20.Valve 34 lays respectively between temperature controller 30 and the additional filter 32 in cold air input line and cold air output lead 24,26, so as safeguard or other operation sequences in hermetically drying chamber 16.
A pump or aerator 36 are installed between additional gas filter 32 and the cooling system 20 in air output lead 26, cold air is circulated between cooling system 20 and hothouse 16.Air inlet and air outlet valve 38 are positioned at the import 40 and outlet 42 places of each cooling chamber 22, each cooling chamber are separated separately, so that safeguard or other operation sequences with circulating cold air line 24,26.In addition, bypass valve 44 is arranged in bypass valve line 46, and this line makes and forms fluid between cold air input line 24 and the cold air output lead 26 and connect, so that hothouse 16 is when disconnecting with cooling system 20, the cold air in the cooling system 20 still can circulate.
Because nozzle 14 is arranged in hothouse 16, the operating temperature of nozzle 14 is lower than the freezing point of the mixture that enters nozzle 14, and therefore, spray valve 14 is freezing easily, hinders mixture to atomize with suitable manner in hothouse 16.Therefore, on valve 14, connected heating tape 48, made the valve temperature be kept above the freezing point of mixture.Other conventional methods that make the temperature of nozzle 14 be kept above the mixture freezing point also can adopt, as known to those skilled in the art.
In operating process, atomizing API passes through nozzle inlet chamber 16, and is solidified by the cold air from cooling system 20 inlet chambers 16 rapidly.Circulation gas should make granule remain on the fluidisation attitude in chamber 16.Remain on the fluidisation attitude and be collected in the process in the filter 28 at granule, the circulation cold gas can be removed and is wrapped in the liquid in the refrigerated solid particle in chamber 16, thereby makes particle drying.The lasting circulation of cold air can make the humidity in every granule be reduced to insignificant degree.After elementary drying is finished, can choose wantonly circulating air progressively is heated to room temperature, so that in the process of taking out sample, carry out secondary drying and reduce also tide.
Line 24 is cooled off in the input that nozzle 14 should make aerosolized mixture spray in the chamber 16.But, should be understood that nozzle 14 can point to output cooling line 26, or other any one side of hothouse 16, to optimize spraying-freezing-normal pressure-dry run.In addition, nozzle 14 can be selected, and producing various atomizing particle sizes, thereby satisfies the needs of any given API and medication.
Perhaps, can choose wantonly and take out the lyophilization granule from filter 28, and send in dry freeze device or other appropriate device, these devices are worked under reduced pressure, and residual moisture can be removed at this, and granule obtains finish-drying.Also in freezing state, the dry freeze device just begins to remove the moisture in the granule to granule, and moisture directly becomes gas phase from solid phase, as known in the art.
In spraying-freezing-normal pressure-dry run, introduce spray step and can solution be processed into dry particulate matter near under the condition of normal pressure.Can formed aerocolloidal API easily near processing spray chilling material under the normal pressure, these API are fit to the dispensing patient to be used.In addition, the method for introduction of the present invention is for providing economic approach at commercial production proper A PI.
1b) use the vibrated fluidized bed of being with internals to prepare the method and apparatus of the present invention's spraying-freezing-normal pressure-dry pharmaceutical compositions
A version of Figure 1A apparatus shown is seen Figure 1B.This variant comprises vibration tool (49) and special internals (50).Vibration component and internals can make the frozen solid granule reach the fluidisation attitude, because they are passing through sublimation drying near in the non-pressurized dry cold airflow.When frozen particle was relatively more sticking, the method was particularly useful.When fluidisation and the freezing powder of elutriation viscosity, this method is very valuable in the process that forms muffin.
In order to improve productive rate, can design a system of sealing fully, prevent freezing powder escape.The powder that available filter disc or papery filter disc or filter paper capture are come out from following fluid bed elutriation.When fluidisation and the freezing powder of elutriation viscosity, vibration component, internals, mechanical agitation member or their combination are very useful.In sublimation process, the frozen particle permeability increases (having lightened), and the aerodynamic behavior changes.The part dried granules can go out the loose filter cake of interruption-forming at filter disc, can utilize dry cold airflow that residual moisture is therefrom being removed near distillation under the normal pressure.
Be similar to the method among the embodiment 1a, send into hothouse 16 by the nozzle API that will atomize, by the cold air that enters hothouse 16 from cooling system 24 freezing rapidly (seeing Fig. 1 b).In operating process, vibrator 49 is transferred to optimum frequency (0-100Hz) and amplitude.Make frozen particle generation fluidisation from the dry cold flow activating QI that cools off line 24 and enter from hothouse 16 bottom surfaces.The bulky grain agglomerate is broken under the help of the special internal member (still) 50 that vibrates and be positioned at chamber 16.Under this operating condition, the channel that cohesive powders will occur usually can reduce or thoroughly eliminate.As a rule, the easy elutriation of little frozen particle, and send into filter 28 by fluidized gas.Muffin on the filter 28 is assembled in fluidisation and elutriation process gradually.
Owing to used above-mentioned granule sealed system, can obtain high flow rate, suggestion is adopted high flow rate in the process that forms muffin, to increase rate of drying.In dry run, also adopt high flow rate, because freezing powder is faster under than slow fluid bed state in the dry rate under the high flow rate fluid bed state.The gas atomization of band vibration component of the present invention and/or internals-freeze-dried process provides economically viable method for production dried particles, increase productive rate.
In addition, higher if desired dry rate can be used in this dry run at a high speed or recirculating fluidized bed.High speed or recirculating fluidized bed generally are made up of the close fluid bed of bottom and the rare fluid bed and the powder send-back system at top.In this process, frozen particle is by cold flow activating QI fluidisation and transport, and is collected by the cyclone separator at top, turns back to close fluid bed by custom-designed powder valve then.For ease of cooling, should use inner cyclone separator, custom-designed returns valve with certain resistance only allows powder to get off, rather than the by-pass activating QI.For the crushed particles agglomerate, increase the granule circulation, also should use similar internals.
Perhaps, choose wantonly and take out the lyophilization granule from filter, and send into dry freeze device or other appropriate device, residual moisture is removed in described dry freeze device or the operation under reduced pressure of other devices, makes the granule finish-drying.Also when freezing state, lyophil apparatus has just been sloughed the moisture in the granule to granule, because moisture is from the solid-state gaseous state that directly become, as known in the art.
The gas atomization of band vibration component of the present invention and/or internals-freeze-dried method provides economically viable method for production dried particles, increase productive rate.
The particulate intranasal administration of embodiment 2 inactivating influenza virus
The particulate dry powder ingredients of the full inactivating influenza virus A/PR/9/34H1N1 of preparation in spraying-lyophilization batch operation.The influenza virus ingredients is sneaked in the aqueous solution, use BD AccuSpray nozzle atomization then.The liquid particles sized data is measured in the about 2 inches place of distance nozzle tip with the Sympatch diffractometer and is obtained.The particle diameter intermediate value that produces under these concentration is about 50 microns.See Fig. 4 with the typical particle diameter distribution that BD AccuSpray nozzle produces.Liquid nitrogen is put into Virtis freeze-dried bottle, bottle is placed on below the nozzle.About 3 inches of distance between nozzle and the liquid nitrogen.Atomized drop is with freezing immediately after liquid nitrogen contacts.Bottle is connected on the dry freeze device, and unnecessary liquid nitrogen is evaporated rapidly.Refrigerated aerosol is generally dry within 48 hours, and water content is lower than about 1wt%.
In an experiment, measure the immunoreation intensity of the various influenza vaccines ingredients generations of carrying by intranasal (IN) or muscle (IM).This research is object of study with the Mus, has measured following several groups:
Group 1-IN.100 μ g influenza * Ag is in 50 μ l liquid
Group 2-IM injection.100 μ g influenza * Ag are in 50 μ l liquid
Group 3-IN administration.100 μ g influenza * Ag in the 10mg trehalose, the lyophilization powder
Group 4-IN administration.100 μ g influenza * Ag in 10mg trehalose+chitosan, the lyophilization powder
Group 5-IN administration.100 μ g influenza * Ag in 10mg trehalose+chitosan, spraying-freeze-dried (SFD) powder
Group 6-IN administration.Has only the cryodesiccated trehalose of 100mg
* the full influenza virus A/PR/8/34H1N1 of deactivation
Mus is respectively at the 0th week, the 3rd week and 3 vaccines of the 6th week inoculation.Collect blood serum sample in the 3rd week, the 5th week and the 8th week, collect nasal wash in the 8th week.
Behind each inoculation influenza vaccines, blood sampling is measured the immunoreation amplitude to influenza vaccines, the concrete antibody response of measuring vaccine (Ab).After each inoculation, also measure the amount of powder of sending into.Measure such as factors such as immunoreation power and powder conveying capacities with conventional method.Figure 2 shows that each postvaccinal serum Ab titre.Generally speaking, though the serum Ab accumulation titre of sending into by IM is higher than the titre of sending into by intranasal, even the spray chilling that IN sends into-dry influenza vaccines dosage lower (being low to moderate 0-10% when inoculating for the second time) also can reach quite high serum Ab reaction.Generally speaking, this experiment shows that under the sufficient situation of vaccine dose, the serum Ab reaction level that the atomizing freeze drying influenza vaccines of IN input can cause is suitable with the IM group, and than IN liquid group height.
As shown in table 1, all IN influenza vaccines groups can both cause positive nose IgA reaction, and IM injection and IN negative control group obtain negative nose IgA titre.This studies show that IN input SFD influenza vaccines can cause nasal mucosa reaction and systemic immunity reaction simultaneously.
Table 1 nose IgA titre
Group 1 (IN, liquid) Organize 2 IM Organize 3 IN, powder Organize 4 IN, chitosan Organize 6 SFD, chitosan Organize 7 IN, trehalose
????80 ??<20 ????<20 ????20 ????40 ????<20
????160 ??<20 ????80 ????20 ????40 ????<20
????160 ??<20 ????<20 ????40 ????40 ????<20
????160 ??<20 ????20 ????40
Embodiment 3 IN input contains/not behind the SFD influenza vaccines of chitosan-containing, and the immunoreactive comparison of serum and nasal mucosa
This embodiment has compared containing and the not immunoreation of the SFD influenza all-virus of chitosan-containing to brown Norway Mus IN input various dose.Respectively organize sample below having measured, every group contains 4 Mus:
1-IN。1 μ g influenza * Ag, in the 5mg trehalose, SFD
2-IN。1 μ g influenza * Ag, in 5mg trehalose+chitosan, SFD
3-IN。10 μ g influenza * Ag, in the 5mg trehalose, SFD
4-IN。10 μ g influenza * Ag, in 5mg trehalose+chitosan, SFD
Present embodiment adopts the full influenza virus strains A/PR/8/34H1N1 of deactivation.Every Mus IN inoculates 3 times.The result shows that the influenza vaccines of the comparable 1 μ g of the influenza vaccines of 10 μ g dosage cause stronger serum I g and nose IgA reaction, and the ingredients of the comparable not chitosan-containing of the ingredients of chitosan-containing causes stronger serum Ab reaction.
Embodiment 4 influenza activity researchs
A series of experiments and process of lapping can influence the influenza immunocompetence.Under study for action, use hemagglutinin result of laboratory test (HA) as the active index of influenza.This chemical examination detects the HA titre of influenza vaccines, and the ability that it condenses the chicken erythrocyte based on influenza virus, this ability are to weigh the index of influenza vaccines effect.In brief, two inactivating influenza virus particulate samples of preparation; First sample dry freeze, second sample elder generation dry freeze grinds then.This sample grinds with Wig-L-Bug microsphere grinding machine.This grinder adopts one inch rustless steel bottle with cover.Sample is put into bottle, the single stainless steel ball of load, cover lid is fixed on the grinder then.This bottle vibrates from the beginning to the end with certain speed, and this speed at the appointed time can change in the section.After the grinding, take out sample with little scraper.Influenza powder freezing and that grind recovers original liquid influenza vaccines concentration (based on total protein concentration) again.Influenza virus activity after the recovery can be determined by the HA titre and the initial flow influenza vaccine that compare them.The gained result is as follows:
Initial liquid influenza vaccines HA titre>6,000 ten thousand
Dry freeze influenza vaccines HA titre>6,000 ten thousand
Dry freeze abrasive flow influenza vaccine HA titre=4352
Initial liquid influenza vaccines HA titre>6,000 ten thousand
Spraying-freeze-dried influenza vaccines HA titre>6,000 ten thousand
These data show that with regard to the HA titre, the dry freeze process does not have much affect to vaccine activity.But process of lapping sharply descends the HA titre.Determined the activity whether the SFD method influences influenza vaccines with identical HA titre.Influenza vaccines powder with the preparation of SFD method returns to initial liquid influenza vaccines concentration (in total protein concentration).Reconstruct influenza vaccines activity is determined by the HA titre of they and primary flow influenza vaccine relatively.
The result shows that the SFD method does not cause harmful effect to the influenza vaccines activity, and administration is convenient in the influenza vaccines powder energy free-flow of preparation, can keep vaccine activity fully simultaneously, does not need to increase in addition grinding operation.
The IN input of the plain enzyme of embodiment 5 plasmid DNA (" naked DNA ") coding fluorescence
Efficient gene is treated and need be from the protein expression of input gene based on the immunity of DNA.For this reason, reporter gene system commonly used is as the archetype of determining that this therapy is whether feasible.The activity of importing luciferase after various DNA dosage and the ingredients by IN has been measured in this research.
A. liquid formulation
In used plasmid, the luciferase coded sequence of Lampyridea is subjected to the control of CMV promoter (pCMV-LUC).PCMV-LUC obtains from the Aldevron LLC that is positioned at North Dakota State Fa Geshi the 15th street No. 3233 (postcodes 58104).The preparation liquid formulation, the dosage of preparation 50 μ g or 100 μ g in 50 μ l PBS is input to the ingredients of these two kinds of dosage in the brown Norway Mus body by IN.DNA is after 24 hours in input, collects nose tissue and lung tissue, and homogenize is with the activity of fluorescence assays method mensuration luciferase.
Figure 5 shows that the uciferase activity of in the nose tissue, measuring, rather than in lung tissue, measure.It is higher than the uciferase activity that 50 μ g DNA obtain that IN imports 100 μ g DNA.
B. the comparison of liquid and dry powder ingredients
Prepare the pCMV-LUC liquid formulation as mentioned above.According to embodiment 4 described dry freeze and Ginding process, prepare dry powder (FD) as excipient with trehalose.Also there is the chitosan excipient in some ingredients.The liquid formulation of preparation 100 μ g dosage in 50 μ l PBS, preparation 100 μ g dosage of powder ingredients in the total powder weight of 5mg are imported their in mouse body, as mentioned above analyzing samples.
Fig. 6 shows that dry powder and liquid formulation can both obtain high uciferase activity in the nose tissue, and lung tissue can not.IN input dry powder can obtain the uciferase activity suitable with liquid formulation.This result demonstrates the probability with SFD powder type input DNA.
Embodiment 6 DNA influenza vaccines
Prepared plasmid with conventional recombinant technique, wherein be subjected to the CMVPro sequence control (Robinson etc. (1995) of CMV early promoter for influenza virus surface antigen hemagglutinin coded DNA sequence, Vaccine 95, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp.69-75).With routine techniques plasmid purification (pFLU-HA), be inoculated in the mouse body: muscle (IM), intranasal, liquid formulation (IN-liquid) and intranasal SFD, contain trehalose excipient (IN-SFD-trehalose) with several method.Measure serum Ab reaction.As shown in Figure 3, the serum Ab reaction that the SFD influenza vaccines of IN input cause is suitable with the IM injection at least, and is higher than the reaction that the input of IN liquid causes.In this research, IN SFD influenza vaccines demonstrate the characteristics that are better than conventional IM injection by kind.
Embodiment 7 usefulness DNA influenza vaccines carry out immunity
Initial results based on IN DNA powder input as implied above is the immunoreation of more various dna vaccination ingredients, has carried out more massive research.The liquid formulation (in PBS) or the dry powder ingredients that have prepared the pFLU-HA plasmid, the wherein optional trehalose/chitosan that comprises.Two types dried ingredients: FD (standard freeze-dried ingredients) and SFD (spraying-freeze-dried (dry freeze) ingredients) have been used.The every kind of dried ingredients that contains 50 μ g plasmid DNA is by intranasal (IN) administration, and quite the liquid formulation of dosage is by in muscle (IM) or the IN input brown Norway Mus body, and the time was respectively the 0th day, the 21st day and the 42nd day.Get serum sample at the 21st, 35 and 56 day, got nasal wash at the 56th day.
Fig. 7 shows that the powder gained serum antibody titer of IN input is suitable with the IM injection, and stronger than the liquid formulation of IN input.At immune commitment, the Ab reaction that IN SFD/ chitosan ingredients causes is the strongest.This shows, uses SFD/ chitosan ingredients and can reduce dosage of inoculation and/or administration frequency.
Table 2 shows that the minority animal in several groups of samples that carry out IN SFD DNA input, all experimental grouies all lack nose IgA reaction.
Table 2 nose IgA titre
??IM IN liquid ??FD The FD/ chitosan ????SFD The SFD/ chitosan
Mus 1 ??<10 ????<10 ??<10 ????<10 ????<10 ????<10
Mus 2 ??<10 ????<10 ??<10 ????<10 ????<10 ????<10
Mus 3 ??<10 ????<10 ??<10 ????<10 ????<10 ????<10
Mus 4 ??<10 ????<10 ??<10 ????<10 ????<10 ????<10
Mus 5 ??<10 ????<10 ??<10 ????<10 ????10 ????10
Mus 6 ??<10 ????<10 ??<10 ????<10 ????<10 ????10
Mus 7 ??<10 ????<10 ??<10 ????<10 ????<10 ????<10
Mus 8 ??<10 ????<10 ??<10 ????<10 ????<10 ????<10
Mus 9 ??<10 ????<10 ????<10 ????<10
The total result of this research demonstrates SFD/ chitosan DAN ingredients and cause potential advantage in better serum and the nasal mucosa immunoreation in animal model.
Embodiment 8 influenza dna fundamental immunities+viral booster immunization scheme
Be a lot of diseases recently, the immunization method that comprises HIV exploitation is so-called " basis-reinforcement " method, wherein primary " basis " immune and secondary " booster immunization " adopt different types of vaccine (Immunology Today, Apr 21 (4), 163-165,2000).For example, kind of a plasmid dna vaccination be can lead, subgroup protein inactivation of viruses or carrier DNA preparation reseeded then.This research is adopted this method to probe into by different immunization routes and combination approach and is imported immunoreation usefulness after the various ingredients.
The preparation in liquid or dried ingredients (contain/do not contain the FD of trehalose/chitosan and contain/do not contain the SFD of trehalose/chitosan) of pFLU-HA plasmid is as described in embodiment 5.These ingredients are used for No. 1 and No. 2 immunity (fundamental immunity).
For carrying out No. 3 immunity (booster immunization), preparation inactivated influenza vaccine in PBS (liquid formulation) or trehalose/chitosan (dry powder ingredients).Every component becomes 2 subgroups: a winding is subjected to IM flow of liquid influenza virus vaccine, and another winding is subjected to various IN influenza virus vaccine ingredients.
At the 0th, 21 and 42 day the brown Norway Mus is selected the various ingredients of inoculation.Got serum sample at the 21st, 35 and 56 day, got nasal wash at the 56th day, wash vaginal secretion and BAL.
Each vaccination regimen and Ab reaction are summarized in table 3A-3G.These data show:
It is stronger than the serum influenza Ab titre that causes with DNA or virus inoculation separately that DNA basic vaccination+influenza virus adds strong virus.
IN SFD/ chitosan DNA basic vaccination+IM virus booster shot reacts stronger than the nose IgA that causes with DNA or IM virus inoculation separately.
IN SFD/ chitosan DNA basic vaccination+IM virus booster shot is stronger than the nose IgA reaction that IN FD/ chitosan DNA basic vaccination+booster shot of IM virus causes.
IN SFD/ chitosan DNA basic vaccination+IM virus booster shot is stronger than the nose IgA reaction that the scheme of the same race without chitosan causes.
IN SFD/ chitosan DNA basic vaccination+IM virus booster shot is stronger than the nose IgA reaction that IN liquid dna basic vaccination+booster shot of IM virus causes.
In the BAL of all groups liquid, all detect positive IgA and total Ig titre.
Table 3 is depicted as the trial of influenza dna fundamental immunity+viral booster immunization.Table 3A is depicted as influenza dna fundamental immunity and booster immunization test: the first hemorrhage serum total Ig titre (the 21st day).Table 3B is depicted as influenza dna fundamental immunity and booster immunization test: the second hemorrhage serum total Ig titre (the 35th day).Table 3C is depicted as influenza dna fundamental immunity and booster immunization test: the 3rd hemorrhage serum total Ig titre (the 56th day).Table 3D is depicted as influenza fundamental immunity and booster immunization test: nose IgA titre (the 56th day).Table 3E is depicted as influenza fundamental immunity and booster immunization test: sheath IgA titre (the 56th day).Table 3F is depicted as influenza fundamental immunity and booster immunization test: the total IgA titre of BAL (the 56th day).
As show shown in the 3A-3C, the powder group in this research can cause stronger serum Ab titre than liquid group generally.In addition, the strong nose IgA reaction that IN SFD/ chitosan basis immunity+IM booster immunization (table 3D 5a group) causes is beat all, because no matter be separately with dna immunization or use the IM virus immunity separately, what cause all is that positive nose IgA reacts.IN SFD DNA/ chitosan basis immunity+IM booster immunization is stronger than IN DNA or the independent immunoreation that causes of IM viral vaccine.
Table 3A
Group Group 1 Group 2 Group 3 Group 4 Group 5
Immunity (DNA) IN liquid ????IN?FD ??IN?SFD IN FD/ chitosan IN SFD/ chitosan
Mus 1 ??<50 ????6400 ??51200 ????6400 ???6400
Mus 2 ??<50 ????12800 ??12800 ????3200 ???25600
Mus 3 ??1600 ????6400 ??25600 ????6400 ???6400
Mus 4 ??400 ????6400 ??12800 ????25600 ???25600
Mus 5 ??<50 ????800 ??6400 ????25600 ???3200
Mus 6 ??<50 ????25600 ??6400 ????12800 ???3200
Mus 7 ??800 ????25600 ??12800 ????12800 ???12800
Mus 8 ??<50 ????12800 ??12800 ????6400 ???25600
Mus 9 ??200 ????12800 ??12800 ????3200 ???25600
Mus 10 ??<50 ????12800 ??12800 ????12800 ???3200
Average titer ??300 ????12240 ??16640 ????11520 ???13760
Table 3B
Group Group
1 Group 2 Group 3 Group 4 Group 5
Immunity 1+2 (DNA) IN liquid ?IN?FD ??IN?SFD IN FD/ chitosan IN SFD/ chitosan
Mus
1 ??400 ?12800 ??102400 Dead ????12800
Mus 2 ??400 ?51200 ??12800 ????12800 ????25600
Mus 3 ??1600 ?6400 ??25600 ????51200 ????12800
Mus 4 ??<50 ?25600 ??25600 ????51200 ????51200
Mus 5 ??200 ?1600 ??25600 ????6400 ????3200
Mus 6 ??50 ?25600 ??51200 ????51200 Dead
Mus 7 ??3200 ?12800 ??102400 ????12800 ????25600
Mus 8 ??<50 ?25600 ??12800 Dead Dead
Mus 9 ??1600 ?25600 Dead ????25600 Dead
Mus
10 ??200 ?25600 ??6400 ????102400 ????25600
Average titer ??765 ?21280 ??40533 ????39200 ????22400
Table 3C
Group Group 1A Group 1B Group 2A Group 2B Group 3A
Immunity
1+2 (DNA) IN liquid IN liquid ??IN?FD ??IN?FD ??IN?SFD
Immunity 3 (viruses) ??IM IN liquid ??IM ??IN?FD ??IM
Mus
1 ??51200 ??25600 ??409600 ??819200 ??819200
Mus 2 ??25600 ??102400 ??819200 ??819200 ??819200
Mus 3 ??819200 ??25600 ??819200 ??819200 ??819200
Mus 4 ??51200 ??409600 ??409600 ??819200
Mus 5 ??102400 ??12800 ??409600 ??819200 ??819200
Mus 6 ??819200
Average titer ??249600 ??43520 ??573440 ??737280 ??819200
Table 3C (continuing)
Group Group 3B Group 4A Group 4B Group 5A Group 5B
Immunity
1+2 (DNA) ?IN?SFD IN FD/ chitosan IN FD/ chitosan IN SFD/ chitosan IN SFD/ chitosan
Immunity 3 (viruses) ?IN?SFD ??IM IN FD/ chitosan ??IM IN SFD/ chitosan
Mus
1 ?819200 Dead ????409600 ??1638400 Dead
Mus
2 ?1638400 ??1638400 ????409600 ??1638400 ????204800
Mus 3 Dead ??3276800 Dead ??1638400 Dead
Mus 4 ?409600 ??3276800 ????819200 ??1638400 Dead
Mus 5 ??819200 ????819200 ??819200 ????102400
Mus 6
Average titer ?955733 ??2252800 ????614400 ??1474560 ????153600
Table 3D
Group Group 1A Group 1B Group 2A Group 2B Group 3A
Immunity
1+2 (DNA) IN liquid IN liquid ????IN?FD ????IN?FD ????IN?SFD
Immunity 3 (viruses) ??IM IN liquid ????IM ????IN?FD ????IM
Mus
1 ??<10 ??20 ????<10 ????40 ????<10
Mus 2 ??<10 ??40 ????<10 ????40 ????<10
Mus 3 ??<10 ??40 ????<10 ????20 ????<10
Mus 4 ??<10 ??20 ????<10 ????40 ????<10
Mus 5 ??<10 ??<10 ????<10 ????40 ????<10
Mus 6 ????<10
Average titer ??<10 ??24 ????<10 ????36 ????<10
Table 3D (continuing)
Group Group 3B Group 4A Group 4B Group 5A Group 5B
Immunity
1+2 (DNA) ????IN?SFD IN FD/ chitosan IN FD/ chitosan IN SFD/ chitosan IN SFD/ chitosan
Immunity 3 (viruses) ????IN?SFD ????IM IN FD/ chitosan ????IM IN SFD/ chitosan
Mus
1 ????160 Dead ????40 ????10 Dead
Mus
2 ????40 ????<10 ????10 ????40 ????40
Mus 3 Dead ????<10 Dead ????40 Dead
Mus 4 ????40 ????<10 ????40 ????20 Dead
Mus 5 ????<10 ????20 ????<10 ????80
Mus 6
Average titer ????80 ????<10 ????27.5 ????22 ????60
Table 3E
Group Group 1A Group 1B Group 2A Group 2B Group 3A
Immunity
1+2 (DNA) IN liquid IN liquid ????IN?FD ????IN?FD ????IN?SFD
Immunity 3 (viruses) ????IM IN liquid ????IM ????IN?FD ????IM
Mus
1 ????<8 ????<8 ????<8 ????<8 ????16
Mus 2 ????<8 ????<8 ????<8 ????<8 ????<8
Mus 3 ????<8 ????<8 ????<8 ????<8 ????<8
Mus 4 ????<8 ????<8 ????<8 ????<8 ????<8
Mus 5 ????<8 ????<8 ????<8 ????<8 ????<8
Mus 6 ????<8
Table 3E (continuing)
Group Group 3B Group 4A Group 4B Group 5A Group 5B
Immunity
1+2 (DNA) ????IN?SFD IN FD/ chitosan IN FD/ chitosan IN SFD/ chitosan IN SFD/ chitosan
Immunity 3 (viruses) ????IN?SFD ????IM IN FD/ chitosan ????IM IN SFD/ chitosan
Mus
1 ????<8 Dead ????<8 ????<8 Dead
Mus
2 ????<8 ????<8 ????<8 ????<8 ????<8
Mus 3 Dead ????<8 Dead ????<8 Dead
Mus 4 ????<8 ????<8 ????<8 ????<8 Dead
Mus 5 ????<8 ????<8 ????<8 ????<8
Mus 6
Table 3F
Group Group 1A Group 1B Group 2A Group 2B Group 3A
Immunity
1+2 (DNA) IN liquid IN liquid ????IN?FD ????IN?FD ????IN?SFD
Immunity 3 (viruses) ????IM IN liquid ????IM ????IN?FD ????IM
Mus
1 ????4 ????4 ????4 ????16 ????64
Mus 2 ????<1 ????4 ????4 ????4 ????4
Mus 3 ????2 ????32 ????<1 ????4 ????4
Mus 4 ????<1 ????16 ????<1 ????4 ????<1
Mus 5 ????2 ????4 ????2 ????2 ????2
Mus 6 ????32
Table 3F (continuing)
Group Group 3B Group 4A Group 4B Group 5A Group 5B
Immunity
1+2 (DNA) ????IN?SFD IN FD/ chitosan IN FD/ chitosan IN SFD/ chitosan IN SFD/ chitosan
Immunity 3 (viruses) ????IN?SFD ????IM IN FD/ chitosan ????IM IN SFD/ chitosan
Mus
1 ????32 Dead ????16 ????16 Dead
Mus
2 ????16 ????4 ????<1 ????32 ????8
Mus 3 Dead ????2 Dead ????4 Dead
Mus 4 ????16 ????16 ????16 ????16 Dead
Mus 5 ????4 ????<1 ????4 ????8
Mus 6
Table 3G
Group Group 1A Group 1B Group 2A Group 2B Group 3A
Immunity
1+2 (DNA) IN liquid IN liquid ????IN?FD ????IN?FD ????IN?SFD
Immunity 3 (viruses) ????IM IN liquid ????IM ????IN?FD ????IM
Mus
1 ????64 ????32 ????256 ????256 ????4096
Mus 2 ????32 ????128 ????256 ????256 ????2048
Mus 3 ????256 ????32 ????256 ????512 ????256
Mus 4 ????8 ????64 ????256 ????128 ????512
Mus 5 ????64 ????8 ????64 ????256 ????128
Mus 6 ????1024
Average titer ????85 ????53 ????218 ????282 ????1344
Table 3G (continuing)
Group Group 3B Group 4A Group 4B Group 5A Group 5B
Immunity
1+2 (DNA) ????IN?SFD IN FD/ chitosan IN FD/ chitosan IN SFD/ chitosan IN SFD/ chitosan
Immunity 3 (viruses) ????IN?SFD ????IM IN FD/ chitosan ????IM IN SFD/ chitosan
Mus
1 ????128 Dead ????128 ????512 Dead
Mus
2 ????1024 ????256 ????32 ????1024 ????256
Mus 3 ????256 Dead ????128 Dead
Mus 4 ????512 ????1024 ????128 ????1024 Dead
Mus 5 ????512 ????256 ????512 ????32
Mus 6
Average titer ????555 ????512 ????136 ????640 ????144
The insulin of embodiment 9 usefulness SD and the preparation of SFD method and the insulin that contains excipient
What table 4 had been summed up measuring is the spraying-drying of excipient and the physical property of spraying-freeze-dried analgesic composition with the lactose.In the forming process of these compositionss, from the outlet temperature of the solution of nebulizer ejection with particulate yield percentage and bulk density (g/cm 3) detected together.Sample and data list are as follows:
Table 4
Solution Process Bulk density (g/cm 3)
Purified insulin Spray drying ????0.29
40/60: insulin/lactose Spray drying ????0.49
Purified insulin Atomizing freeze drying (SFD) ????0.01
40/60: insulin/lactose Atomizing freeze drying (SFD) ????0.06
It is as shown in the table, and the bulk density of 40/60 solution of the purified insulin of atomizing freeze drying and insulin/lactose is significantly less than spray-dired insulin and insulin/lactose granule.The SFD powder composition can keep protein stability and biological activity better than spray-dried compositions.On the contrary, spray-dired purified insulin and insulin/lactose (40/60) powder is obviously more closely knit, and bulk density is 0.29 and 0.49g/cm 3Though do not want to be subjected to the constraint of any particular theory, the present patent application people believes why have these advantages to be because the conventional spraying-baking temperature of temperature ratio that spraying-freeze-dried takes place low (low 100 ℃ approximately).
With spraying-freeze-dried of the present invention (dry freeze) method processing 2wt% insulin solution and 5wt% insulin/lactose (40/60), the gained porous particle has aerocolloidal character, is fit to be transported in the respiratory system of animal.
Applicant's test shows, the minimum aerodynamic particle diameter that obtains with the atomizing freeze drying method is the insulin that does not contain excipient, promptly is the particle diameter of the insulin of pure substance basically.But, should be appreciated that by insulin and excipient and form but the ingredients that can satisfy with the purpose of respiratory system administration is also included within the scope of the invention.In addition, compare with spray drying insulin/lactose granule, SFD insulin granule (Figure 19) is exposed to common temperature damp condition (20 ℃ 53%RH) after following 15 minutes, and are nearly all detected generation less than hydration in storage.Otherwise Figure 20 has shown that SFD insulin/lactose granule is exposed to the form that identical common temperature damp condition is kept after following 15 minutes.Usually, SFD insulin/lactose granule be exposed to>50% relative humidity following time will absorb the moisture of 2-5wt% at least.These results show, compare with SFD porous insulin/lactose, and the SFD porous insulin for preparing with the inventive method has higher resistance to common dampness.
The powder that remains in the conveyer device after another speciality that the inventive method has is to use greatly reduces.The percent dose that the particular delivery device is taken in can be calculated by weight.For example, API prepared according to the methods of the invention, when using with the 09/758776 described conveyer device that is registered in January 12 calendar year 2001 by the U.S. Patent application 09/879517 that is registered in June 12 calendar year 2001, powder residual in conveyer device is less than 5%.As a comparison, the spray-dried powders that remains in the conveyer device of the same race is about 20wt%.In addition, can observe by naked eyes, it is very high that the SFD powder forms aerocolloidal process efficiency, do not have residual powder in the respiratory system conveyer device basically.After the medicament carrier capsule that includes SD (lower-left capsule) and SFD (upper right capsule) powder takes out from this device, the breakable capsule film, its photo is shown in Figure 21, and this figure has clearly showed the aerosol character of SFD powder excellence.
The stability of embodiment 10 SFD insulin powder and liquid insulin relatively
Mensuration has also compared SFD insulin and the stability that contains the U500 liquid Lilly Humulin-R of metacresol, and the latter is current widely used normal fluid insulin.SFD purified insulin and insulin/trehalose measured for 8 weeks under 40 ℃ and 75% humidity.Measured the purified insulin that is sealed in the aluminum packing equally.The liquid insulin is measured under 25 ℃ (room temperatures) and 60% relative humidity.Measure the percentage ratio of the amide of formation, determine each stability of sample thus with respect to sample.The formation percent of amide at the beginning, 1 week, 2 weeks, 4 weeks, 6 weeks and measured in 8 weeks.
Known amide can produce immunity to insulin in patient's body, so diabetics is had harmful effect.FDA regulation insulin lactams content must be lower than 10%.
Experiment showed, that the SFD purified insulin is all especially stable in the mensuration in whole 8 weeks.The measurement result of SFD purified insulin is:
In 1 week of beginning in 6 all 8 weeks of 4 weeks in 2 weeks
% amide 0 0.329 0 0.222 1.015 2.66
SFD purified insulin sample with the aluminum parcel shows chemical stability at whole 8 all test periods.Up to the 6th week, the amount of detected amide is lower than statistical error, thereby can ignore.The detection peak of amide occurred in the 6th week, was 0.75%.Measurement result with the SFD purified insulin of aluminum parcel is as follows:
In 1 week of beginning in 6 all 8 weeks of 4 weeks in 2 weeks
% amide 0 0.396 0.12 0 1.752 0.750
The SFD insulin that with the trehalose is excipient also obtains measuring.In this case, just detect amide up to the 6th week.On the whole, add the preservation life-span that trehalose has obviously improved the SFD insulin.
The result is as follows:
In 1 week of beginning in 6 all 8 weeks of 4 weeks in 2 weeks
% amide 0000 0.24 1.57
The reference fluid insulin was measured for 8 weeks equally, to determine the recruitment of amide.Experiment shows that in 8 all test periods, the stability of liquid insulin is more far short of what is expected than SFD insulin.Except measuring, also measured the liquid insulin at the 24th and 72 hour by week.In these early stage mensuration, do not detect the increase of amide.Measure under the condition of storage that but a remarkable parameter of this research is the liquid insulin a little less than than the SFD insulin Duos.In addition, the liquid insulin contains the chemical preservative metacresol, in order to slow down the increase of amide.
In 1 week of beginning in 6 all 8 weeks of 4 weeks in 2 weeks
% amide 0 1.216 1.23 1.32 1.640 2.13
Experiment shows that each SFD insulin sample is all much stable than the liquid insulin.The liquid insulin is obviously more faster than the degraded of SFD powder.With the SFD insulin of aluminum parcel is under 40 ℃ and 75% relative humidity condition, the most stable sample in 8 all minutes.The result shows that the SFD powdered insulin is much more stable than present commercial liquid insulin ingredients.
Figure 10 has shown that the amide of SFD purified insulin and liquid insulin advances the speed.
Embodiment 11 vibrated fluidized bed atomizing freeze dryings
Introduce in other places as this description, in the presence of internals and vibration component, under near normal pressure (antivacuum), can successfully prepare the porous particle of spraying-freeze-dried.Experiment shows that the fluid mapper process under internals and vibration component help can promote freezing aerocolloidal distillation.In less than 40 minutes time, under-20 ℃, 20wt% mannitol solution (Figure 11) (promptly containing 80wt% moisture) is dried to 0.3wt%.This is better than the result that Leuenberger (USP 4608764) etc. obtains.
The moisture of 20wt% mannitol and drying time, (as the function of dry gas speed) was shown in Figure 11.The minimum drying curve that presents in the table produces in BDT, and other data are then selected from document Leuenberger (USP 4608764).From TGA result, after under the gas velocity of 2m/s dry 40 minutes, residual moisture is about 0.3%.SEM among Figure 12 shows that granule has the porous form.In spray chilling aerosol, have strong adhesive power between granule and the fluidized gas, thereby be easy to pass fluid bed and upwards form channel less than 20 μ m.Dry and during not by internals and vibration component under 0.39m/s ,-20 ℃ of conditions when the spray chilling powder, the powder of finding 95wt% after dry 3 hours is owing at the bottom of channel is retained in bed.Channel in the fluid bed makes the drying effect variation.The powder elutriation of about 5wt% is (after dry 3 hours) to bed top, and its dry rate is more faster than the powder at the bottom of being collected in bed.The elutriation process is, when gas superficial speed is higher than granule/agglomerate tail speed, fluidized gas just with the fine grained band from fluid bed.Embodiment 12 has explained dry gas speed and elutriation effect in the fluid bed by analysis of mass transfer.Figure 14 shows that in the humidity of each time point at the sample of bed top and the collection of the bed end.Has only 5% spray chilling powder elutriation to the drying bed top.At the bottom of 95% freezing powder is retained in bed; The drying efficiency difference is attributable to channel.Elutriation is taken a sample at the 30th and 60 minute to the powder (collecting with filter disc) on bed top, and its SEM figure sees Figure 15 and 16.The powder for drying that the powder of collecting in the 60th minute was collected unlike the 30th minute.After sample took out, the new elutriation exsiccant powder of part that comes out was sneaked in the more exsiccant powder, causes particulate reunion.Under internals and vibration component help, all elutriations form uniform cake to the powder on fluid bed top, therefore eliminated channel and efficient drying is provided.As shown in figure 17, under the higher dry gas speed of 2m/s, 20wt% mannitol is dried to the speed of voluminous powder (0.3wt% is surplus wet) than faster under the low dry gas speed of 0.39m/s.Figure has shown in vibrated fluidized bed SFD process, flow velocity and distillation time relation.In the presence of vibration component and internals, all powder elutriation is to the drying bed top.High flow rate makes drying faster, so drying efficiency is also higher.
The analysis of mass transfer of dry run in embodiment 12 fluid beds and the fixed bed drying device
The particulate final sedimentation rate of 20 μ m is about 0.012m/s (speed=ρ pd p 2G/18 μ), it is corresponding to the single frozen particle in the elutriation process.Under so low gas flow rate (low reynolds number), mass tranfer coefficient is very low.Richardson and Szekely (1961) have set up following empirical equation, and mass tranfer coefficient k and Reynolds number in the gas-solid fluidized bed are associated.
Sh=0.37R e 1.8??0.1<Re<15,
Wherein Sh is sherwood number (=kd p/ D), k is a mass tranfer coefficient, D is a diffusion coefficient, d pBe particle diameter, Re is Reynolds number (=ρ pUd p/ μ).If the particulate mass size is d a=200 μ m, density of nitrogen is 1.29kg/m 3, nitrogen flow rate is 1.81 * 10 -5Kg/m/s (Pa*s), fluid rate are 0.012m/s (20 μ m individual particle tail speed.If fluidized gas speed is higher than individual particle tail speed, because the agglomerate in the fluid bed collides and fricative individual particle will be pulled away or elutriation is come out), (Re=0.171), then Sh is 1.54 * 10 -2
When dry gas speed is higher than 0.012m/s, granule (20 μ m or littler) will go out from the fluid bed elutriation, need collect with filter or cyclone separator.All outside granule tail speed, filter disc is collected powder in the process of the freezing powder of cold dry gas stream continuous drying in the operation of Leuenberger and BDT.As a result, coming out in the elutriation of fluid bed top exit in clammy agar end, forms even cake.Out-of-date when the dry gas high velocity stream, dry run is similar to the fixed bed drying device.The mass transport process of fixed bed also can be passed through Ranz (1952) at Chem.Eng.Prog.48, and another empirical equation that proposes in 247 calculates:
Sh=2.0+1.8Sc 1/3Re 1/2
Wherein, Sc is Schmidt number (=μ/ρ gD).When Re was higher, for example working as particle diameter was 20 μ m, and density of nitrogen is 1.29kg/m 3, nitrogen viscosity is 1.81 * 10 -5Kg/m/s, fluid rate are 2.0m/s (be 60 liters/minute, source nitrogen pressure is 40psi) in our experiment, and then Sh is 4.7 as calculated.By the mass transport process between gas and the solid in relatively lower Re fluid bed and the high Re fixed bed, can draw two kinds of mass transfer ratios under the situation and be about 1: 300.
In one group of experiment, drying nitrogen speed is 0.03m/s, is used for dry 5wt%PEG solution (95% moisture).Under this flow velocity, some powder elutriate (collecting with filter paper) are arranged.But, on filter paper, do not observe " powder ", because these frozen particles bone dry has not as yet thawed again in the time of on depositing to filter paper.The freezing sample of collecting at the bottom of bed after 4 hours of fluidisation (real fluidisation) still contains 93% moisture.This observed result is supported our sherwood number analysis, and promptly fluid mapper process is slow, mass transfer (drying) speed difference.
According to above description, those skilled in the art are easy to determine basic feature of the present invention.Under the prerequisite that does not deviate from original intention of the present invention and scope, can make various changes and modifications to the present invention, to adapt to various uses and condition.
Need not to give unnecessary details, we believe the description of those skilled in the art by the front, can utilize the present invention fullest.Therefore, the preferred implementation of preceding mask body can only be interpreted as exemplary, rather than to any restriction of other situations of the present invention.
Above with accompanying drawing in all applications, patent and the document quoted, its full content is hereby incorporated by reference.

Claims (56)

1. with a kind of pharmaceutical composition of method preparation, described method comprises:
Nebulae inhalation disease or prophylactic liquid ingredients produce the atomizing ingredients;
Freezing described atomizing ingredients forms solid granulates;
Dry described solid granulates forms dried particles,
The volume mean diameter of wherein said dried particles between 35-300 μ m, the volume diameter of 50% the dried particles of wherein having an appointment at least average diameter about 80% within, the average air power diameter of described dried particles is between about 8-140 μ m.
2. the described pharmaceutical composition of claim 1, the volume mean diameter that it is characterized in that described dried particles is between 50-300 μ m.
3. the described pharmaceutical composition of claim 1, the volume mean diameter that it is characterized in that described dried particles is between 50-100 μ m.
4. the described pharmaceutical composition of claim 1, the average air power diameter that it is characterized in that described dried particles is between about 20-70 μ m.
5. the described pharmaceutical composition of claim 1, it is characterized in that described freezing by being lower than fluid from described liquid formulation freezing point to temperature or medium in introduce described atomizing ingredients and carry out.
6. the described pharmaceutical composition of claim 5 is characterized in that the boiling point of described fluid or medium or boiling point or the sublimation point that sublimation point is lower than described atomizing ingredients.
7. the described pharmaceutical composition of claim 5 is characterized in that described fluid is a gas.
8. the described pharmaceutical composition of claim 5 is characterized in that described fluid is a liquid.
9. the described pharmaceutical composition of claim 1 is characterized in that described granule is by the dry freeze drying.
10. the described pharmaceutical composition of claim 1 is characterized in that described granule near under the normal pressure, and is dry in the presence of vibration component, internals, mechanical agitation member or their combinations.
11. the described pharmaceutical composition of claim 10 is characterized in that described dried particles is further by the dry freeze drying.
12. the described pharmaceutical composition of claim 1 is characterized in that described therapeutic agent is protein, nucleic acid or virion.
13. the described pharmaceutical composition of claim 1 is characterized in that described therapeutic agent is an immunoreagent.
14. the described pharmaceutical composition of claim 13 is characterized in that described immunoreagent is influenza vaccines.
15. the described pharmaceutical composition of claim 14 is characterized in that described influenza vaccines comprise inactivating influenza virus granule or nucleic acid coding influenza hemagglutinin protein matter, it effectively is connected with the CMV promoter.
16. the described pharmaceutical composition of claim 1 is characterized in that described therapeutic agent is an insulin.
17. the described pharmaceutical composition of claim 1 is characterized in that described liquid formulation comprises mucoadhesive.
18. the described pharmaceutical composition of claim 17 is characterized in that described mucoadhesive is chitosan, dermatan sulfate, chrondroitin or pectin.
19. the described pharmaceutical composition of claim 1 is characterized in that described liquid formulation mainly is made up of therapeutic agent and water.
20. the pharmaceutical composition by following method preparation: nebulae inhalation disease or prophylactic liquid ingredients produce the atomizing ingredients; Freezing described atomizing ingredients forms solid granulates; Dry described solid granulates, form dried particles, the volume mean diameter of described dried particles is between 35-300 μ m, wherein have an appointment at least 50% dried particles volume diameter average diameter about 80% within, the average air power diameter of described dried particles is between about 8-140 μ m.
21. comprise the pharmaceutical composition of dried particles and pharmaceutical carrier, the average air power diameter that it is characterized in that described dried particles is between about 8-140 μ m, volume mean diameter between 35-300 μ m, the volume diameter of 50% the dried particles of wherein having an appointment at least average diameter about 80% within.
22. with a kind of pharmaceutical composition of method preparation, described method comprises:
Nebulae inhalation disease or prophylactic liquid ingredients produce the atomizing ingredients, and described atomizing ingredients comprises the droplet of volume mean diameter between 35-300 μ m;
Freezing described atomizing ingredients forms solid granulates;
Dry described solid granulates forms dried particles,
The volume mean diameter of wherein said dried particles between 35-300 μ m, the volume diameter of 50% the dried particles of wherein having an appointment at least average diameter about 80% within, the average air power diameter of described dried particles is between about 8-140 μ m.
23. the method for a pharmaceutical compositions, described method comprises:
Nebulae inhalation disease or prophylactic liquid ingredients produce the atomizing ingredients;
Freezing described atomizing ingredients forms solid granulates;
Dry described solid granulates forms dried particles,
The volume mean diameter of wherein said dried particles between 35-300 μ m, the volume diameter of 50% the dried particles of wherein having an appointment at least average diameter about 80% within, the average air power diameter of described dried particles is between about 8-140 μ m.
24. the described method of claim 23, the volume mean diameter that it is characterized in that described dried particles is between 50-300 μ m.
25. the described method of claim 23, the volume mean diameter that it is characterized in that described dried particles is between 50-100 μ m.
26. the described method of claim 23, the average air power diameter that it is characterized in that described dried particles is between about 20-70 μ m.
27. the described method of claim 23, it is characterized in that described freezing by being lower than fluid from described liquid formulation freezing point to temperature or medium in introduce described atomizing ingredients and carry out.
28. the described method of claim 27 is characterized in that the boiling point of described fluid or medium or boiling point or the sublimation point that sublimation point is lower than described atomizing ingredients.
29. the described method of claim 27 is characterized in that described fluid is a gas.
30. the described method of claim 27 is characterized in that described fluid is a liquid.
31. the described method of claim 23 is characterized in that described granule is by the dry freeze drying.
32. the described method of claim 23 is characterized in that described granule near under the normal pressure, and is dry in the presence of vibration component, internals, mechanical agitation member or their combinations.
33. the described method of claim 23 is characterized in that described drying unites near under the normal pressure drying and dry freeze drying in the presence of vibration component, internals, mechanical agitation member or their combinations.
34. the described method of claim 23, described therapeutic agent are protein, nucleic acid or virion.
35. the described method of claim 23 is characterized in that described therapeutic agent is an immunoreagent.
36. the described method of claim 35 is characterized in that described immunoreagent is influenza vaccines.
37. the described method of claim 36 is characterized in that described influenza vaccines comprise inactivating influenza virus granule or nucleic acid coding influenza hemagglutinin protein matter, it effectively is connected with the CMV promoter.
38. the described method of claim 23 is characterized in that described therapeutic agent is an insulin.
39. the described method of claim 23 is characterized in that described liquid formulation comprises mucoadhesive.
40. the described method of claim 39 is characterized in that described mucoadhesive is chitosan, dermatan sulfate, chrondroitin or pectin.
41. the described method of claim 23 is characterized in that described liquid formulation mainly is made up of therapeutic agent and water.
42. the method for a pharmaceutical compositions, described method comprises: nebulae inhalation disease or prophylactic liquid ingredients produce the atomizing ingredients; Freezing described atomizing ingredients forms solid granulates; Dry described solid granulates, form powder, described powder comprises the dried particles of volume mean diameter between 35-300 μ m, wherein have an appointment at least 50% dried particles volume diameter average diameter about 80% within, the average air power diameter of described dried particles is between about 8-140 μ m.
43. a Therapeutic Method, it comprises the described pharmaceutical composition of claim 1 of using effective dose to the patient that demand is arranged.
44. the described method of claim 43, it is characterized in that described compositions by in the respiratory system, intranasal, internal rectum, intravaginal, Sublingual or parenteral administration.
45. the described method of claim 43 is characterized in that described compositions dispenser to nasal mucosa.
46. a Therapeutic Method, it comprises the described pharmaceutical composition of claim 20 of using effective dose to the patient that demand is arranged.
47. a Therapeutic Method, it comprises the described pharmaceutical composition of claim 10 of using effective dose to the patient that demand is arranged.
48. a method that reduces the therapeutic agent consumption, described consumption are that this method comprises the described pharmaceutical composition of claim 1 of using effective dose by intranasal to the patient to the required dosage of generation curative effect behind patient's Nasacort.
49. in patient's body, cause immunoreactive method, comprise the described immune composition of claim 13 of using effective dose to described patient.
50. the described method of claim 49 is characterized in that described compositions passes through intranasal administration.
51. the described method of claim 50 is characterized in that described immune composition is influenza vaccines.
52. the described method of claim 51 is characterized in that described influenza vaccines comprise inactivating influenza virus granule or nucleic acid coding influenza hemagglutinin protein matter, it effectively is connected with the CMV promoter.
53. the described method of claim 51 is characterized in that described influenza vaccines comprise inactivating influenza virus granule or influenza virus subunit.
54. the described method of claim 49 is characterized in that described immune composition uses as the part of basis-reinforcement course of treatment.
55. the described method of claim 54 is characterized in that using described immune composition in the fundamental immunity, uses virus formulation in the booster immunization.
56. the described method of claim 54 is characterized in that fundamental immunity passes through intranasal administration, booster immunization is by the muscle administration.
CNA028260074A 2001-11-19 2002-11-19 Pharmaceutical compositions in particulate form Pending CN1607941A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US33195201P 2001-11-19 2001-11-19
US60/331,952 2001-11-19
US33915601P 2001-12-11 2001-12-11
US60/339,156 2001-12-11
US41995902P 2002-10-22 2002-10-22
US60/419,959 2002-10-22

Publications (1)

Publication Number Publication Date
CN1607941A true CN1607941A (en) 2005-04-20

Family

ID=27406830

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA028260074A Pending CN1607941A (en) 2001-11-19 2002-11-19 Pharmaceutical compositions in particulate form
CNB028262204A Expired - Fee Related CN1287770C (en) 2001-11-19 2002-11-19 Pharmaceutical compositions in particulate form

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB028262204A Expired - Fee Related CN1287770C (en) 2001-11-19 2002-11-19 Pharmaceutical compositions in particulate form

Country Status (11)

Country Link
US (3) US7842310B2 (en)
EP (2) EP1455754A4 (en)
JP (2) JP2005532987A (en)
KR (2) KR20050044523A (en)
CN (2) CN1607941A (en)
AU (2) AU2002346424A1 (en)
BR (2) BR0214280A (en)
CA (2) CA2466982A1 (en)
MX (2) MXPA04004726A (en)
WO (2) WO2003072016A2 (en)
ZA (1) ZA200403848B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102830222A (en) * 2012-09-20 2012-12-19 成都斯马特科技有限公司 Method for preparing solid granular biochemical reagent
CN104198717A (en) * 2014-08-30 2014-12-10 中国科学院苏州生物医学工程技术研究所 Freeze-drying concentrated glucose detection reagent microsphere and preparation method thereof

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
MXPA04004726A (en) * 2001-11-19 2004-07-30 Becton Dickinson Co Pharmaceutical compositions in particulate form.
US20040042972A1 (en) * 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
EP1592443B1 (en) * 2003-02-13 2011-03-30 Becton, Dickinson and Company Improved anthrax vaccines and delivery methods
JP2006518748A (en) * 2003-02-20 2006-08-17 ベクトン・ディキンソン・アンド・カンパニー Powder formulation of recombinant staphylococcal enterotoxin B (<SB> R </ SB> SEB) made by atmospheric pressure spray lyophilization for improved vaccination
US20040209361A1 (en) * 2003-04-18 2004-10-21 Hemperly John J. UV-cross-linked PVA-based polymer particles for cell culture
GB0315632D0 (en) * 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
CA2435632A1 (en) * 2003-07-21 2005-01-21 Warren Hugh Finlay Formulation of powder containing nanoparticles for aerosol delivery to the lung
DE10339197A1 (en) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried amorphous powder with low residual moisture and good storage stability
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
JP2007534633A (en) * 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド Human alpha 1-antitrypsin preparation
WO2005061088A1 (en) * 2003-12-22 2005-07-07 Finlay Warren H Powder formation by atmospheric spray-freeze drying
US7007406B2 (en) 2004-01-23 2006-03-07 Zhaolin Wang Powder formation by atmospheric spray-freeze drying
EP1734993A4 (en) * 2004-04-01 2009-10-21 Alza Corp Apparatus and method for transdermal delivery of influenza vaccine
WO2006008006A1 (en) * 2004-07-23 2006-01-26 Bayer Technology Services Gmbh Sterile freezing, drying, storing, assaying and filling process (sfd-saf process) (pellet freeze-drying process for parenteral biopharmaceuticals)
WO2007053923A2 (en) * 2005-11-11 2007-05-18 Biolab Sanus Farmacêutica Ltda. Solid pharmaceutical composition comprising agglomerate nanoparticles and a process for producing the same
US8097245B2 (en) 2005-12-28 2012-01-17 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
US20080075777A1 (en) * 2006-07-31 2008-03-27 Kennedy Michael T Apparatus and methods for preparing solid particles
JP2010502747A (en) * 2006-09-08 2010-01-28 ベクトン・ディキンソン・アンド・カンパニー A stable powder formulation of alum-adsorbed vaccine
EP1915987A1 (en) * 2006-10-27 2008-04-30 MediGene AG Spray-freeze-drying process for the preparation of pellets comprising percolation drying
AU2007322075B2 (en) * 2006-11-17 2013-07-25 Genetronics, Inc. Methods of enhancing immune response using electroporation-assisted vaccination and boosting
WO2008076975A1 (en) 2006-12-18 2008-06-26 Advanced Bionutrition Corporation A dry food product containing live probiotic
EP1972347A1 (en) 2007-03-19 2008-09-24 Becton, Dickinson and Company, Wagner, Jaconda Stable vaccine powder formulations
GB0707612D0 (en) * 2007-04-19 2007-05-30 Stratosphere Pharma Ab Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
TWI436789B (en) * 2008-01-21 2014-05-11 Intervet Int Bv Method for lyophilising particles having a pharmaceutical compound contained therein and a pharmaceutical pack containing such particles
CA2986751A1 (en) 2009-03-27 2010-09-30 Intervet International B.V. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
JP5804453B2 (en) * 2009-05-14 2015-11-04 国立大学法人 東京大学 Crystalline polyol fine particles and preparation method thereof
KR101799983B1 (en) 2009-05-26 2017-12-20 어드밴스드 바이오뉴트리션 코프. Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
AR080073A1 (en) 2010-01-28 2012-03-14 Advanced Bionutrition Corp VITREA DRY COMPOSITION THAT INCLUDES A BIOACTIVE MATERIAL
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
EP2689785B1 (en) 2010-04-15 2021-05-19 Shin Nippon Biomedical Laboratories, Ltd. Method for generating dry vaccine powder formulation for inranasal delivery
JP5996837B2 (en) * 2010-05-28 2016-09-21 小林製薬株式会社 Influenza virus infection inhibitor
US9945611B2 (en) 2010-08-04 2018-04-17 Ima Life North America Inc. Bulk freeze drying using spray freezing and agitated drying
EP2601466B1 (en) 2010-08-04 2017-10-04 IMA Life North America Inc. Bulk freeze drying using spray freezing and stirred drying
ES2676656T3 (en) 2010-08-13 2018-07-23 Advanced Bionutrition Corp. Dry storage stabilizer composition for biological materials
KR101875245B1 (en) 2010-12-02 2018-08-02 온콜리틱스 바이오테크 인코포레이티드 Liquid viral formulations
JP6034797B2 (en) 2010-12-02 2016-11-30 オンコリティクス バイオテク,インコーポレーテッド Lyophilized virus preparation
EP2747815B1 (en) 2011-09-07 2017-11-29 Concentrx Pharmaceuticals, Inc. Dry powder inhalation device
EP2578974A1 (en) * 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
US8956566B2 (en) 2012-03-12 2015-02-17 Pure Biosolutions, Llc System and method for virus inactivation
EP2671591B1 (en) * 2012-06-08 2017-08-09 Corden Pharma Brussels Process for the preparation of short-chain peptide powders
DK3082771T3 (en) 2013-12-19 2019-09-02 Aerosol Therapeutics Llc COMPOSITIONS AND METHODS FOR ATMOSPHERIC SPRAY FREEZER DRYING
JP5837670B2 (en) * 2014-10-24 2015-12-24 アイエムエー ライフ ノース アメリカ インコーポレーテッド Bulk freeze drying using spray freezing and stirring drying
WO2016077190A1 (en) * 2014-11-10 2016-05-19 National Institutes Of Health Probiotic therapeutic applications
WO2016165831A1 (en) 2015-04-17 2016-10-20 Curevac Ag Lyophilization of rna
EP3916091A3 (en) 2015-05-20 2022-03-30 CureVac AG Dry powder composition comprising long-chain rna
EP3297682B1 (en) 2015-05-20 2021-07-14 CureVac AG Dry powder composition comprising long-chain rna
BR112018001784B1 (en) 2015-07-29 2022-05-10 Advanced Bionutrition Corp Stable dry probiotic compositions for special dietary uses, their method of preparation and method of preparing an infant formula
WO2017040265A1 (en) * 2015-08-28 2017-03-09 Nanotherapeutics, Inc. Norovirus vaccine
TWI590817B (en) 2015-10-14 2017-07-11 鈺邦科技股份有限公司 Impregnation apparatus and impregnation method
WO2018111778A1 (en) * 2016-12-13 2018-06-21 Qool Therapeutics, Inc. Dense phase material transport in pulmonary system
CN106889058B (en) * 2017-02-20 2019-07-19 徐小杨 A kind of cell freeze-drying system and method
CN110494181B (en) 2017-03-28 2022-03-18 康森特里克斯药物公司 Device and method for delivering dry powder medicament
WO2019021957A1 (en) * 2017-07-25 2019-01-31 第一三共株式会社 Dry powder pharmaceutical composition for nasal instillation
CN107875407A (en) * 2017-12-15 2018-04-06 天津梅花生物医药科技有限公司 A kind of new bulk drug sterile processing systems
IT201900023046A1 (en) * 2019-12-05 2021-06-05 Vomm Impianti E Processi S P A Product in the form of a powder comprising lactose and its production process
CN111269444A (en) * 2020-01-22 2020-06-12 苏州新丝原生物科技有限公司 Crosslinked microsphere and preparation method and application thereof
WO2021211624A1 (en) * 2020-04-14 2021-10-21 Qool Therapeutics, Inc. Frozen particle generator using liquid micro-dispenser
CA3173146C (en) * 2020-11-16 2023-10-31 Joel Peter LENNON-MEYER Continuous throughput lyophilizer/powder filler within a sterile boundary
CN112484396A (en) * 2020-12-29 2021-03-12 南通联源机电科技股份有限公司 A vibrated fluidized bed that is used for dry desilt of fine work sand to use
CN114272372A (en) * 2021-12-28 2022-04-05 方坦思(上海)生物医药有限公司 Monoclonal antibody freeze-dried powder preparation and preparation process thereof
WO2023138670A1 (en) * 2022-01-21 2023-07-27 The University Of Hong Kong Dual targeting powder formulation of antiviral agent for nasal and lung deposition through single intranasal administration

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US656871A (en) * 1898-03-11 1900-08-28 Walter Rushton Under screen for carding-engines.
US656888A (en) * 1899-09-30 1900-08-28 Winfield S Haines Engine-valve.
US2798835A (en) * 1954-01-18 1957-07-09 American Cyanamid Co Newcastle disease and infectious bronchitis vaccines and production thereof
US2946724A (en) * 1957-05-29 1960-07-26 American Cyanamid Co Stable poliomyelitis live virus vaccine
US3313032A (en) * 1966-07-28 1967-04-11 George J Malecki Freeze-drying process and apparatus
US3957965A (en) 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1163470A (en) 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
DK126720B (en) * 1968-05-11 1973-08-13 Leybold Heraeus Verwaltung Apparatus for continuous freeze-drying.
FR7461M (en) 1968-06-19 1970-01-05
US3932943A (en) * 1970-08-14 1976-01-20 E. I. Du Pont De Nemours And Company Method of preparation of lyophilized biological products
NL7012832A (en) * 1970-08-29 1972-03-02
FR2299011A1 (en) * 1975-01-29 1976-08-27 Obert Jean Claude PART AEROSOL GENERATOR
US4323478A (en) 1977-01-18 1982-04-06 Baxter Travenol Laboratories, Inc. Novel particulate compositions
DE2965725D1 (en) 1978-07-19 1983-07-28 Patrick Couvreur Biodegradable nanoparticles, pharmaceutical compositions containing them and process for their preparation
US4251509A (en) * 1980-01-31 1981-02-17 Wisconsin Alumni Research Foundation Dry particulate vaccine for oral administration
EP0058021A3 (en) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmaceutical compositions
JPS59163313A (en) 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
CH664005A5 (en) 1984-05-19 1988-01-29 Glatt Maschinen & Apparatebau METHOD FOR DRYING A PARTICLE-SHAPED GOOD AND DEVICE FOR CARRYING OUT THE METHOD.
JPS61194034A (en) 1985-02-25 1986-08-28 Teijin Ltd Powdery composition for transnasal administration
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
CA1336401C (en) * 1987-10-15 1995-07-25 Brian H. Vickery Intranasal administration of polypeptides in powdered form
JPH0739339B2 (en) * 1989-05-01 1995-05-01 アルカーメス コントロールド セラピューティクス,インコーポレイテッド Method for producing small particles of bioactive molecule
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
NL9000207A (en) 1990-01-29 1991-08-16 Duphar Int Res
US5208998A (en) * 1991-02-25 1993-05-11 Oyler Jr James R Liquid substances freeze-drying systems and methods
JPH07503154A (en) 1992-01-21 1995-04-06 エス・アール・アイ・インターナシヨナル Improved preparation method for miniaturized polypeptide drugs
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
US6290962B1 (en) 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
IS1796B (en) * 1993-06-24 2001-12-31 Ab Astra Inhaled polypeptide formulation composition which also contains an enhancer compound
GB9316745D0 (en) * 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
JPH07112940A (en) * 1993-08-26 1995-05-02 Takeda Chem Ind Ltd Sustained-release parenteral preparation and its production
WO1995009649A1 (en) * 1993-10-05 1995-04-13 Medeva Holdings B.V. Vaccine compositions
US5902565A (en) 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
NZ281112A (en) 1994-03-07 1998-04-27 Inhale Therapeutic Syst Powdered insulin delivered as an aerosol
MX9605717A (en) 1994-05-18 1998-05-31 Inhale Therapeutic Syst Methods and compositions for the dry powder formulation of interferons.
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
SE9404468D0 (en) 1994-12-22 1994-12-22 Astra Ab Powder formulations
JP3098401B2 (en) 1995-07-12 2000-10-16 株式会社エルティーティー研究所 Formulation for nasal administration
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
WO1997007788A2 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
GB9522351D0 (en) 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
EP0862419B2 (en) * 1995-11-09 2010-11-17 Microbiological Research Authority Microencapsulated dna for vaccination and gene therapy
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
DE19612967A1 (en) * 1996-04-01 1997-10-02 Behringwerke Ag Process for the propagation of influenza viruses in cell culture, and the influenza viruses obtainable by the process
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5908825A (en) * 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US20030096259A1 (en) * 1999-08-24 2003-05-22 Medlmmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs), homogeneous VLP and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6554497B2 (en) * 1998-01-28 2003-04-29 Fuji Photo Film Co., Ltd. Compact camera
US6328967B1 (en) 1998-03-12 2001-12-11 Allergenics, Inc. Delivery system to modulate immune response
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
GB9810126D0 (en) * 1998-05-13 1998-07-08 Glaxo Group Ltd
WO2000014547A1 (en) 1998-09-04 2000-03-16 Powderject Research Limited Immunodiagnostics using particle delivery methods
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
DE60021059T2 (en) 1999-02-03 2006-05-18 Powderject Research Ltd. A particulate pharmaceutical composition for transdermal particle delivery from a needleless syringe system
WO2000066206A2 (en) * 1999-05-03 2000-11-09 Battelle Memorial Institute Compositions for aerosolization and inhalation
GB9916316D0 (en) * 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
AU2001231000A1 (en) 2000-01-19 2001-07-31 Pharmaceutical Discovery Corporation Dry powder formulations of antihistamine for nasal administration
EP1118331A1 (en) * 2000-01-21 2001-07-25 I.D.M. Immuno-Designed Molecules Method for enhancing the presentation of exogenous antigen by human antigen-presenting cells and opsonized micro particle complexes for applying this method
US6585957B1 (en) * 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
CA2400468C (en) 2000-02-15 2012-12-18 Intellivax International Inc. Proteosome influenza vaccine
US20020009463A1 (en) * 2000-02-23 2002-01-24 Jan Raa Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
US6584782B2 (en) * 2000-02-25 2003-07-01 Glatt Gmbh Method for producing particulate goods
GB0004827D0 (en) * 2000-02-29 2000-04-19 Quadrant Holdings Cambridge Compositions
NZ552576A (en) * 2000-06-08 2008-06-30 Powderject Vaccines Inc Salt adjuvant-containing gel-forming free flowing compositions in a powder form for transdermal delivery from a needless syringe
US20020120228A1 (en) 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
MXPA03001092A (en) 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation.
US6565888B1 (en) * 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
US20020128179A1 (en) 2000-12-01 2002-09-12 Tacon William C. Shaped microparticles for pulmonary drug delivery
WO2002043705A2 (en) 2000-12-01 2002-06-06 University Of Florida Aerodynamically light vaccine for active pulmonary immunization
CA2433335C (en) * 2000-12-29 2010-04-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
CA2436418A1 (en) 2001-01-30 2002-08-08 Board Of Regents, The University Of Texas Systems Process for production of nanoparticles and microparticles by spray freezing into liquid
US6485707B2 (en) * 2001-02-15 2002-11-26 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6596262B2 (en) 2001-02-15 2003-07-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6544497B2 (en) * 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6551578B2 (en) 2001-02-15 2003-04-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20030009149A1 (en) * 2001-06-08 2003-01-09 Yasmin Thanavala Method for nasal application of a medicinal substance
AU2002302814A1 (en) * 2001-06-08 2002-12-23 Powderject Vaccines, Inc. Spray freeze-dried compositions
US6537265B2 (en) 2001-06-08 2003-03-25 Health Research, Inc. Method for nasal application of a medicinal substance
DK1418890T3 (en) * 2001-08-16 2008-08-11 Baxter Int Propellant-based microparticle formulations
US20030044771A1 (en) 2001-08-30 2003-03-06 Anderson Norman G. Method for discovering new infectious particles
DK1450856T3 (en) 2001-09-14 2010-05-31 Cytos Biotechnology Ag Packaging of Immunostimulatory CpG in Virus-Like Particles, Method and Use
WO2003031583A2 (en) * 2001-10-09 2003-04-17 University Of Miami Generation of virus-like particles by vsv
MXPA04004726A (en) * 2001-11-19 2004-07-30 Becton Dickinson Co Pharmaceutical compositions in particulate form.
DK1455755T3 (en) * 2001-11-20 2013-07-15 Civitas Therapeutics Inc Improved particle composition for delivery in lung
US20040042972A1 (en) * 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
US20040092470A1 (en) * 2002-06-18 2004-05-13 Leonard Sherry A. Dry powder oligonucleotide formualtion, preparation and its uses
JP2006518748A (en) * 2003-02-20 2006-08-17 ベクトン・ディキンソン・アンド・カンパニー Powder formulation of recombinant staphylococcal enterotoxin B (<SB> R </ SB> SEB) made by atmospheric pressure spray lyophilization for improved vaccination
US7007406B2 (en) * 2004-01-23 2006-03-07 Zhaolin Wang Powder formation by atmospheric spray-freeze drying

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102830222A (en) * 2012-09-20 2012-12-19 成都斯马特科技有限公司 Method for preparing solid granular biochemical reagent
CN104198717A (en) * 2014-08-30 2014-12-10 中国科学院苏州生物医学工程技术研究所 Freeze-drying concentrated glucose detection reagent microsphere and preparation method thereof
CN104198717B (en) * 2014-08-30 2016-04-06 中国科学院苏州生物医学工程技术研究所 A kind of concentrated glucose determination reagent freeze-drying microballoon and preparation method thereof

Also Published As

Publication number Publication date
CN1287770C (en) 2006-12-06
US20030186271A1 (en) 2003-10-02
BR0214279A (en) 2005-12-20
CA2467833A1 (en) 2003-09-04
EP1455754A2 (en) 2004-09-15
AU2002366267A1 (en) 2003-09-09
CN1607942A (en) 2005-04-20
ZA200403848B (en) 2005-07-27
MXPA04004730A (en) 2004-07-30
WO2003043574A3 (en) 2004-03-04
US20070190158A1 (en) 2007-08-16
WO2003072016A3 (en) 2003-11-20
WO2003072016A2 (en) 2003-09-04
JP2005518430A (en) 2005-06-23
EP1455754A4 (en) 2006-01-18
US7842310B2 (en) 2010-11-30
AU2002346424A1 (en) 2003-06-10
KR20040073438A (en) 2004-08-19
EP1458362A2 (en) 2004-09-22
US20030180755A1 (en) 2003-09-25
MXPA04004726A (en) 2004-07-30
WO2003043574A2 (en) 2003-05-30
EP1458362A4 (en) 2006-01-18
JP2005532987A (en) 2005-11-04
AU2002366267B2 (en) 2007-05-10
BR0214280A (en) 2005-01-11
KR20050044523A (en) 2005-05-12
CA2466982A1 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
CN1607941A (en) Pharmaceutical compositions in particulate form
CN1138531C (en) Dispersible macromolecule compositions and methods for their preparation and use
CN1384733A (en) Dry powder compositions having improved dispersivity
US20050186146A1 (en) Interleukin-13 antagonist powders, spray-dried particles, and methods
CN1441670A (en) Highly efficient delivery of large therapeutic mass aerosol
CN1745170A (en) High pressure spray-dry of bioactive materials
CN1447704A (en) Flow resistance modulated aerosolized active agent delivery
WO2009039502A9 (en) Nanotherapeutic colloidal metal compositions and methods
EP1755677A2 (en) High pressure spray-dry of bioactive materials
US20040213745A1 (en) Powder formulations of rSEB for improved vaccination
EP3113759B1 (en) Vaccine delivery systems using yeast cell wall particles
CN1365275A (en) Methods for coating particles and particles produced thereby
McAdams Production, optimization and characterization of pharmaceutical and excipient powders produced by carbon dioxide-assisted nebulization with a bubble dryer (CAN-BD)
CN1672732A (en) Stable recombinant solid alpha-interferon composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication